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ABSTRACT: 
CC-Chemokine receptor-like 1 (CCRL1) and 2 (CCRL2) are members of the atypical 
chemokine receptor family that are defined by the inability to initiate canonical GPCR 
signalling. CCRL1 has been proposed to be involved in germinal centre 
maintenance, while CCRL2 is thought to be involved in plasma cell function, however 
their exact roles are still unclear. Given their close chromosomal locations, it is 
possible that these genes arose by recent gene duplication and thus have some 
overlapping function. Therefore this study aimed to investigate the antibody 
responses in mice doubly deficient in CCRL1 and CCRL2. Double knockout (DKO) 
mice showed no abnormalities in cell localisation in the spleen or lymph nodes and 
no difference in antibody titres following thymus-dependent (TD) immunisation. 
However, IgM and IgG3 titres were increased in the thymus-independent 2 response. 
In the spleen, B cell numbers were increased at rest, but normal after TD 
immunisation; while in lymph nodes B cell numbers were decreased both before and 
after TD immunisation. Together, the minor difference in phenotype in these DKO 
mice compared to controls indicates separate roles of CCRL1 and CCRL2 in the 
antibody response. Additional studies into these receptors individually will lead to 
further elucidation of their functions. 
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1. INTRODUCTION 
1.1 – Secondary lymphoid organs & B cell activation 
Adaptive immune responses begin in secondary lymphoid organs (SLOs), which 
include lymph nodes (LNs) and the spleen. The spleen is located in the abdomen, 
adjacent to the stomach and just below the diaphragm. Functionally and structurally it 
is comprised of two parts: the red pulp, important for filtering blood – removing aged 
erythrocytes, bacteria and cellular debris; and the white pulp, involved in adaptive 
immune responses and the generation of antibody1. The white pulp consists of a 
central arteriole surrounded by the periarteriolar sheath (PALS) or T cell zone (TZ) 
where T cells and dendritic cells (DCs) interact. Around the TZ are B cell follicles 
where germinal centres can form as part of an immune response. Surrounding this 
structure is the marginal zone (MZ) which contains marginal zone macrophages 
(including marginal zone metallophilic macrophages), marginal zone B cells and a 
subset of dendritic cells. Exterior to the MZ is the marginal sinus which separates the 
white pulp from red pulp areas and allows entry of immune cells to the white pulp1. 
Lymph nodes act as garrisons for the immune system, formed at specific sites to 
sample antigens from the nearby tissue and augment the response against invading 
pathogens. LNs are comprised of an outer cortex and an inner medulla. Lymph 
enters via the afferent lymphatic vessels and travels through the cortical sinuses, into 
the medullary sinuses, and exits via the efferent lymphatics. Immune cells can enter 
the lymph node via this route or via high endothelial venules (HEVs) from the blood2. 
Unlike lymph nodes, the spleen has no afferent lymph vessels - immune cells can 
only enter via the blood1. 
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The structure of the LN, although different, has similarities to that of the splenic white 
pulp. For example, the cortex is comprised of B cell follicles and a deeper 
paracortical area or TZ2. Both areas display a similar cellular composition to those in 
the spleen. In the LN medulla, medullary sinuses are separated by medullary chords 
that contain plasma cells, memory T cells and macrophages2. 
After entering a secondary lymphoid organ, B cells sample both free antigen, and 
antigen held in complexes on follicular dendritic cells (FDCs) in the B cell follicles3. 
Upon interacting with cognate antigen, a B cell will become activated. The fate and 
subsequent response elicited by this B cell will then depend on the nature of the 
antigen, as discussed below. 
1.1.1 –Thymus dependent activation 
Following activation by a conventional protein antigen, B cells are induced to migrate 
towards the TZ. Recognition of the antigen displayed on the B cell surface by a T cell 
will then cause local growth of both cells. B cells can then differentiate via one of two 
main pathways: the extrafollicular pathway, or the germinal centre (GC) response4. 
The extrafollicular pathway enables the rapid production of moderate affinity 
antibody, while the GC response facilitates the selection of high affinity antibody over 
a longer time period. Together, the two pathways allow an extremely efficient 
response to form as pathogens are met quickly with an initial wave of antibody, 
followed by a later wave of antibody of even greater affinity. 
In the extrafollicular response, B cells first upregulate the transcription factor Blimp1 
and differentiate into plasmablasts. These cells migrate to extrafollicular locations 
(such as the red pulp in the spleen) and associate with CD11chigh DCs. These cells 
have shown to be important in aiding B cell survival4. CD138 (syndecan-1), a marker 
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for plasma cells, is progressively upregulated and antibody secretion is increased as 
plasmablasts become fully differentiated plasma cells. Most of these plasma cells 
have an approximate lifespan of 3 days in mice4. 
Alternatively, GCs may form in the B cell follicles, and are comprised of two main 
areas - a light zone (LZ) and a dark zone (DZ) (Fig. 1.1). The DZ is proximal to the T 
cell area while the LZ forms distally. This positioning of the light zone facilitates the 
uptake of antigen by resident follicular dendritic cells (FDCs)5   
The purpose of a GC is to provide a specific niche to allow optimum affinity 
maturation –the process whereby a B cell increases the affinity for target antigen in 
order to generate a more specific humoral response. The classic description of the 
GC response first describes the migration of B cells to the DZ, where they become 
centroblasts. Here they rapidly proliferate and rearrange their antibody variable 
region immunoglobulin genes in a process known as somatic hypermutation5. This 
allows the random generation of higher affinity BCRs by introducing specific point 
mutations. T cell interactions may also promote further Ig heavy chain 
rearrangements that alter the immunoglobulin class - class switch recombination. 
Following this, cells exit the cell cycle and migrate to the LZ to compete for antigen 
held in complexes on FDCs. Successful B cells take up the antigen, while the 
majority of the B cells die by neglect, undergoing apoptosis before they are cleared 
by resident tingible body macrophages. Selected B cells must then receive help from 
follicular helper T (TFH) cells in order to complete the final checkpoint. This help has 
shown to be essential as TFH cells provide ICOS and CD40L signals, without which 
GC development is severely impaired6. The successful B cell can then become 
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Figure 1.1 – Extrafollicular and germinal centre thymus dependent B cell responses in 
secondary lymphoid organs. 
1) A B cell entering the secondary lymphoid organ encounters and internalizes cognate 
antigen and is activated. Antigen is processed and presented on MHC class II molecules. 
CCR7 is upregulated allowing movement towards the T cell zone. T cell activation in the T 
cell zone has also allowed upregulation of CXCR5 and subsequent migration towards the B 
cell follicle (not shown). 2) Cognate B and T cells interact at the T zone border allowing bi-
directional activation. B cells completing this step differentiate down one of two pathways. 3) 
A B cell can exit the follicle and produce relatively low affinity unswitched IgM antibody, or 4) 
The B cell can enter the germinal centre reaction. The cell will first enter the dark zone to 
become a centroblast, proliferating and undergoing somatic hypermutations, before it 
migrates to the light zone as a centrocyte to compete for antigen held on follicular dendritic 
cells. Successful B cells must interact with T follicular helper cells before either exiting the 
germinal centre as high affinity, class switched plasma/memory cells, or undergo repeated 
rounds of affinity maturation to further increase antibody affinity.  
MHC; Major Histocompatability Complex, TZ; T cell zone, F; B cell follicle, MZ; Marginal 
Zone, DZ; Dark Zone, LZ; Light Zone, FDC; Follicular Dendritic Cell. 
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a plasma cell secreting high affinity antibody, or a memory B cell that allows a rapid 
response to secondary challenge7. Alternatively the B cell can migrate back to the 
dark zone and undergo repeated rounds of proliferation, somatic hypermutation and 
selection to increase antibody affinity further (see Fig. 1.1). It is worth pointing out 
that recent studies have indicated not all proliferation and somatic hypermutation 
happens in the DZ. Allen et al. showed cell division and apoptosis occurred in both 
the LZ and the DZ, highlighting the need for an updated model of the GC reaction5. 
1.1.2– Thymus independent activation 
Alternatively, certain antigens can initiate the B cells response without the need of T 
cell help. These are known as thymus independent (TI) antigens, which can be 
subdivided into two types. TI-1 antigens include the bacterial molecule 
lipopolysaccharide (LPS), which activate Toll-like receptors on the surface of B cells 
as well as binding to the BCR. Conversely, TI-2 antigens, such as the polysaccharide 
Ficoll, provoke B cell responses by repeating epitopes cross-linking multiple BCRs. 
The predominant response against TI antigens is the extrafollicular pathway, and 
IgM+ (‘natural’) memory B cells can be formed as part of this response7. GCs are able 
to form in some TI responses, but they are short lived, and break down after 
approximately 4 days in mice, presumably due to the lack of TFH cell involvement. No 
plasma cells or memory B cells are thought to arise from these short lived GCs4. 
1.2 – Chemokines and chemokine receptors in adaptive immune responses 
1.2.1 – Conventional chemokine receptors 
Chemokines (chemotactic cytokines) are small proteins that are involved in cellular 
trafficking and activation, as well as other diverse physiological functions including 
haematopoiesis, angiogenesis and central nervous system development5, 8, 9. 
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Chemokine nomenclature is based on their structure. The main chemokines contain 
four cysteine residues that form disulphide bonds. Chemokines can be classified into 
groups depending on the amino acid composition at the position of the first and 
second cysteine residues in the sequence10. CC chemokines have no residues 
between these cysteines, whereas CXC- and CX3C chemokines have one or three 
residues respectively. Other chemokine groups lack 2 of the 4 cysteine residues – 
XCL1 and XCL2 chemokines11. Receptors for chemokines are G-protein coupled 
receptors (GPCRs). These are cell surface receptors that contain seven 
transmembrane regions and signal using intracellular G-protein subunits. 
In adaptive immune responses, chemokines are vital for proper cellular positioning 
and colocalisation. Upon uptake of antigen, DCs upregulate CCR7 which allows them 
to enter SLOs as the CCR7 ligand CCL21 is expressed in the efferent lymphatic 
vessels. CCR7 is also important in allowing the migration of DCs to the TZ where 
stromal cells express the two CCR7 ligands CCL21 and CCL19 12. 
CCL19 and CCL21 are also involved in the retention of CCR7+ T cells in the TZ. 
FDCs in the follicles express CXCL13 which is important in retaining CXCR5+ B 
cells12. On recognition of antigen and subseqent activation, T cells downregulate 
CCR7 while upregulating CXCR5, allowing them to move towards the border of the B 
cell follicles. Conversely, once activated by antigen, B cells upregulate CCR7, 
allowing them to move towards the TZ and get help from activated T cells12. 
Once activated at the T cell border, B cells upregulate Epstein-Barr virus-induced G-
protein coupled receptor 2 (EBI2), allowing their coordinated migration towards the 
outer edge of the follicle due to the high abundance of its ligand, EBI2L, in these 
areas13. By day 4 post antigen encounter, GC precursor B cells decrease expression 
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of EBI2 and upregulate sphingosine-1-phosphate receptor 2 (S1PR2) which directs 
migration to the centre of the germinal centre. Upon ligation of sphingosine-1-
phosphate (S1P), S1PR2 inhibits chemokine-directed migration. The highest S1P 
concentrations are thought to be at the GC border, therefore S1PR2 B cells act to 
confine the GC BCs in the GC13. 
GC DZ B cells express high levels of CXCR4, which is necessary for cellular 
retention in the DZ in response to the ligand CXCL12. CXCL12 is thought to be 
produced by stromal cells that are more closely packed in the DZ. Conversely, 
CXCR5 expression is uniform across the GC, and as such downregulation of CXCR4 
allows the GC B cells to respond to CXCL13 signals and move into the light zone to 
compete for antigen5. Interestingly, in the MZ, the atypical chemokine receptor 
CXCR7 was shown to be expressed on MZ B cells acting as a chemokine sink, 
taking up and degrading CXCL1214.  
1.2.2 – Atypical chemokine receptors – CCRL1 and CCRL2 
Atypical chemokine receptors (ACKRs) differ from their conventional chemokine 
receptor counterparts by their inability to the initiate classical GPCR signalling 
response15, 16. The canonical motif DRYLAIV in the second intracellular loop is either 
absent or altered in ACKRs. This abolishes the ability of the receptor to couple to G-
proteins. There are currently five known ACKRs: Duffy Antigen Receptor for 
Chemokines (DARC), D6, CXCR7 and CC-Chemokine receptor like 1 and -2 (CCRL1 
and CCRL2)16. ACKRs share the propensity to internalize chemokines. This uptake is 
followed by either degradation or transport of the chemokine depending on the 
ACKR15. 
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CCRL1 has been shown to be expressed in lymphatic endothelial cells and cortical 
thymic epithelial cells15, 17-19. Initially, it was thought CCRL1 was not expressed on 
hematopoietic cells17, but data from the Immunological genome project and our lab 
show CCRL1 mRNA is present in GC B cells. Our lab has since confirmed this at the 
protein level by immunofluorescence staining [Laura Ibanez - unpublished data]. 
CCRL1 binds the CCR7 ligands CCL19 and CCL21; the CCR9 ligand CCL25 and in 
humans can bind the CXCR5 ligand CXCL13 with low affinity15, 20, 21. Upon ligand 
binding, CCRL1 recruits β-arrestin and is transported, along with the bound 
chemokine, to lysosomes for degradation15, 16. CCRL1-deficient mice show increased 
blood titres of CCL21 as well as increased titres of both CCL21 and CCL19 in lymph 
nodes. Intriguingly, this was coupled with a decreased LN cellularity and reduced DC 
influx to LNs following immune challenge16, 22. This could be as a failure of CCRL1-/- 
mice to establish pro-migratory chemokine patterns or due to CCR7 
desensitisation16. 
CCRL1 may be involved in controlling the gradients of CCL19 and CCL21 in the 
tissue to aid entry of CCR7-expressing immune cells into SLOs15. Similar 
mechanisms may operate in the thymus. Aged CCRL1-deficient mice develop 
autoimmunity, potentially due to abnormal thymocyte migration patterns and failures 
in central tolerance15. Therefore, it could conceivably be the case that CCRL1-
mediated scavenging of CCR7 ligands may help keep CCR7hi T cells out of the GC, 
and permit memory and plasma cells to leave following affinity maturation and 
selection. 
CCRL2 is the most recently discovered member of the ACKR family, and as such it 
has been least characterised. Reports suggest it binds to CCL5 and CCL2, but these 
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findings have not yet been independently confirmed, leading some to question its 
status as a true chemokine receptor16, 23. However, CCRL2 has been shown to bind 
the adipokine chemerin, and in humans it binds and internalizes CCL1916, 24, 25. 
CCRL2 has been shown to be expressed on almost all haemopoetic cells, including 
B cells, T cells, DCs and macrophages16, 26.Within B cell subsets, data from our lab 
have shown CCRL2 expression is highest in plasma cells [Sarah Cook - unpublished 
data]. 
One study demonstrated DCs from CCRL2-deficient mice are defective at 
transporting antigen to mediastinal lymph nodes in a model of airway inflammation27. 
Another study revealed CCRL2 transfected cells are able to concentrate chemerin at 
inflammatory sites, allowing its presentation to another chemerin receptor 
Chemokine-like receptor 1 (CMKLR1)24, 26. Building from this, CCRL2 has also been 
shown to play a role in lymphocyte recruitment.  The CCRL2 expressed on 
endothelial cells concentrated chemerin to the inflammatory site where it mediated 
the recruitment of CMKLR1+ lymphocytes28. Relating to the B cell response, data 
from our lab has shown CCRL2-deficient mice display increased serum IgM titres, 
and splenic plasma cell numbers in response to the TI-2 antigen NP-Ficoll [Sarah 
Cook - unpublished data]. 
1.3 – Study aims 
The little known roles of both CCRL1 and CCRL2 make both these receptors 
interesting options for study. Furthermore, the two receptors are located on the same 
chromosome, and are relatively close proximity – approximately 6MB apart. 
Therefore, in evolutionary terms, it is plausible that these genes arose by recent gene 
duplication and thus may have overlapping functions. For that reason the aims of this 
project were to investigate any differences in antibody responses in mice deficient in 
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both these receptors. Both thymus-dependent and –independent 2 responses were 
comprehensively analysed. In collaboration with two ongoing PhD projects looking at 
the roles of CCRL1 and CCRL2 individually, this work could have important 
implications in unravelling the function and significance of these receptors in B cell 
responses.  
2. MATERIALS AND METHODS 
2.1 – Mice 
All mice were housed at the University of Birmingham biomedical services unit 
(BMSU) and treated according to Home Office guidelines. Wild type (WT) C57 BL/6 
mice were purchased from Harlan Laboratories. CCRL2 deficient mice (CCRL2-/-) 
were purchased from The Jackson Laboratory, ME, USA. CCRL1 deficient mice 
(CCRL1-/-) were a kind gift from R.Nibbs [University of Glasgow]. These two deficient 
strains were then crossed. Crossovers of both genes were identified by producing F1 
hybrid mice, and then by crossing F1 hybrids onto wildtype mice. F2 offspring was 
screened for the presence of both alleles. Presence of a copy of each allele in F2 
mice identified crossovers. These mice were then inbred to produce double deficient 
CCRL1/CCRL2 mice. Heterozygous CCRL1/CCRL2 deficient mice were also 
produced from backcrosses onto the C57 BL/6 strain. 
2.2 – Immunisations 
Immunisations were carried out using both the thymus dependent antigen 
nitrophenol-chicken gamma globulin (NP-CGG) and the thymus independent type II 
antigen 4-hydroxy-nitrophenyl-Ficoll (NP-Ficoll). CGG [Sigma] was conjugated to NP 
by Mrs. Chandra Raykundalia [school of Immunity and Infection, University of 
Birmingham]. 9% aluminium potassium sulphate was mixed with NP-CGG and the 
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pH adjusted to 6.5 to create an alum precipitate. The suspension was mixed in the 
dark before centrifugation (5 mins, 2000rpm). NP-CGG was then washed twice in 
PBS and resuspended in saline at a concentration of 50µg/200µl with 1 x 107 heat 
killed Bordetella pertussis/ml for intraperitoneal (i.p.) injections; or at a concentration 
of 20µg/20µl with 5 x 106 heat killed Bordetella pertussis pertussis/ml for footpad 
injections. Bordetella pertussis was added as a further adjuvant. NP-Ficoll [Biosearch 
Technologies, Novato, CA] was prepared by dissolving the antigen in PBS at a 
concentration of 30µg/200µl. 
2.3 – Isolation of spleen, lymph node and serum 
Blood was extracted by cardiac puncture and incubated briefly at 37°C to allow for 
clotting, before centrifugation (10000rpm, 10 minutes). Supernatant was removed 
and stored at -20°C. Spleens and lymph nodes were isolated by dissection and 
weighed. The central portions of the spleens or whole LN were snap frozen in liquid 
nitrogen or dry ice. The ends of the spleens, along with some LNs, were mashed into 
RPMI 1640 media [Sigma-Aldrich] containing 10% heat inactivated fetal calf serum 
(FCS) and the antibiotics penicillin/streptomycin (RPMI +FCS+P/S). Cells were then 
counted with a haemocytometer, using a 1/10 dilution of trypan blue. Cells were 
centrifuged and resuspended at the appropriate concentration(s). 
2.4 –Flow cytometry 
Cell suspensions were transferred to a 96 well plate. A 1:1 ratio of control and 
knockout (CCRL1/CCRL2-/-) cells were also used for compensations and unstained 
controls. The plate was first centrifuged (4 mins, 1000rpm, 4°C), and the cells 
resuspended with 50µl of anti-FcRγII and –FcRγIII antibodies (to prevent non-specific 
binding) in FACS buffer [Sigma-Aldrich] containing 10% FCS and 2mM EDTA. Cells 
were incubated with this block for 20 minutes at 4°C. Following this, 150µl of wash 
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buffer (RPMI +FCS+P/S) was added to each well, the plate centrifuged (4 mins, 
1000rpm, 4°C) and incubated in 50µl of relevant antibody mixes (20mins at 4°C). 
This incubation step was carried out in the dark to prevent unnecessary 
photobleaching. Cells were then washed twice before being transferred in FACS 
buffer to FACS tubes for running on the flow cytometer. In the case of biotinylated 
antibodies, incubation periods were 1 hour, and then a wash step was carried out 
before streptavidin conjugated to PE Cy-7 was added for 20 minutes. Analysis was 
carried out on a CyAN flow cytometer [Beckman Coulter, UK] using Summit v4.3 
software. FloJo v9.3.2 software was used for subsequent offline analysis. All 
antibodies and dilutions used are listed in table 1.  
2.5 – Immunohistochemistry 
Sections of spleen and LN were cut using a cryostat to a thickness of 6µm, and 
transferred to glass slides. Slides were fixed in acetone (20 mins, 4°C) and stored at 
-20°C until required. For staining, slides were first washed in Tris buffer (pH 7.6) for 
10 minutes and then incubated with primary antibodies (made up in Tris buffer) for 1 
hour at room temperature in a humidity chamber. Slides were then washed in Tris 
buffer for 5 minutes and then secondary antibodies added in Tris buffer with 10% 
normal mouse serum (NMS) [Dako, Ely, UK] to minimise non-specific binding to the 
sections. After a 45 minute incubation period, slides were washed in Tris buffer as 
before. Next, streptavidin complex [Dako] was added to the slides to bind to 
biotinylated secondary antibodies for 45 minutes. After washing, slides were stained 
with horseradish peroxidase substrate 3,3 diaminobenzidine tetrachloride (DAB) 
[Sigma] and visualised after approximately 5 minutes. When slides were adjudged to 
have been sufficiently developed, they were washed and then incubated with the 
substrate for alkaline phosphatase, Fast Blue [Sigma]. Slides were visualised to 
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monitor development and then washed once more. Finally, slides were washed in 
distilled water and mounted using warm glycerol gelatine [Sigma]. Images were taken 
with a Leica CTR6000 microscope using a micropublisher 5.0RTV camera using Q 
Capture software v.2.9.11. Analysis was carried out using ImageJ v.1.46r software. 
All antibodies used are listed in table 1. 
2.6 – Immunofluorescence histology 
Slides were first blocked for 1 hour with 10% normal horse serum in PBS containing 
1% bovine serum albumin (BSA). Relevant primary, secondary and tertiary 
antibodies were then added sequentially. Primary antibodies were incubated for 1 
hour, while secondary and tertiary antibodies were incubated for 45 minutes each. All 
incubation steps were carried out in a dark humidity chamber with 5 minute washing 
steps in phosphate buffered saline (PBS) between each stain. All antibodies were 
made up in PBS – 1% BSA, and secondary antibody solutions also contained 10% 
NMS to prevent non-specific binding. After a final wash step, slides were mounted 
using prolong gold (Life Technologies) and stored in the dark until use. Images were 
taken with the same Leica microscope (see section 2.5), but using LAS AF 
v.2.6.0.7266 software. Analysis was carried out using ImageJ v.1.46r software. All 
antibodies used are listed in table 1. 
2.7 – ELISA 
96 well ELISA plates [Immuno 96 MicroWell solid – Nunc, Thermo Scientific] were 
coated with 5µg/ml NP2-BSA or NP15-BSA in coating buffer (Na2CO3 15mM, NaHCO3 
35mM) overnight at 4°C. NP2-BSA was used to detect high affinity antibody, while 
NP15-BSA was used to detect total antibody. Conjugation of both antigens was 
carried out by Mrs. Chandra Raykundalia [school of Immunity and Infection, 
University of Birmingham]. After incubation, plates were washed in wash buffer (PBS 
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100nM, 0.05% Tween 20, pH 6.8) and blocked to reduce non-specific binding by 
adding 200µl of PBS containing 1% BSA to each well. Plates were incubated for 90 
minutes in a humidity chamber at 37°C. Meanwhile, serum was diluted in PBS as 
required. After washing, serum was serially diluted across the plate to provide a 
range of concentrations to test, allowing for the post-experimental generation of 
standard curves. 
Following another wash step, alkaline phosphatase-conjugated isotype specific 
antibody solutions were added to relevant wells and incubated for 1hr at 37°C. After 
subsequent washing, 100µl of the substrate p-nitrophenyl phosphate (N2770 – 
Sigma-Aldrich) was added to each well and the plate was incubated at 37°C until a 
yellow colour appeared. The plates were read at 405nm using a Synergy HT 
Microplate Reader [Bio-Tek, VT, USA] and SoftMax Pro v.5.4.5 software. Standard 
curves were produced and extrapolated on Microsoft Excel 2010. Results were first 
plotted as dilution against absorbance readings, before a manual threshold y-value 
was assigned at a point of logarithmic decline on the curves (Fig. 2.1). An x-value of 
dilution was then extrapolated from this threshold to give relative titres. 
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Figure 2.1 – Example standard curve to illustrate ELISA analysis. Black horizontal line 
indicates threshold taken to extrapolate dilutions and calculate relative antibody titres. 
 
2.8 – Statistical Analysis 
Data was plotted, analysed and displayed using GraphPad Prism v.5 software. 
Statistical significance was assessed by the non-parametric Mann Whitney U two-
tailed test. P values of <0.05 were accepted as statistically significant.  
2.9 – Antibody list 
Specificity Conjugation Species/Isotype 
Final 
Dilution 
Experiment 
Company 
(Reference no.) 
Mouse IgD - Sheep 1/500 Immunohistochemistry ABCAM (AB9177) 
Mouse IgD - Rat 1/1000 Immunohistochemistry 
BD Pharmingen 
(553438) 
Mouse IgM - Rat 1/600 Immunohistochemistry 
ABD serotec 
(MCA199) 
Mouse IgG - Rat 1/100 Immunohistochemistry 
ABD serotec 
(MCA424) 
Mouse CD3 - Rat 1/500 Immunohistochemistry 
ABD serotec 
(MCA500G) 
Mouse CD138 - Rat 1/100 Immunohistochemistry 
BD Pharmingen 
(553712) 
NP - Sheep 1/3000 Immunohistochemistry In House 
Mouse F4/80 - Rat 1/500 Immunohistochemistry 
ABD serotec 
(MCA497GA) 
Rat Igs Biotin Rabbit 1/600 Immunohistochemistry DAKO (E0468) 
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Specificity Conjugation Species/Isotype 
Final 
Dilution 
Experiment 
Company 
(Reference no.) 
Sheep Igs Peroxidase Donkey 1/100 Immunohistochemistry 
Jackson 
Immunoresearch 
(713-035-147-
JIR) 
Sheep Igs Biotin Donkey 1/100 Immunohistochemistry 
Jackson 
Immunoresearch 
(713-065-147-
JIR) 
Rat Igs Peroxidase Rabbit 1/80 Immunohistochemistry DAKO (P0450) 
Mouse 
CD16/CD32 
- Rat IgG2b,  k 1/200 Flow cytometry 
BD Pharmingen 
(01241A) 
Mouse IgD FITC Rat IgG2a, k 1/300 Flow cytometry 
BD Pharmingen 
(553439) 
Mouse IgM PE-Cy7 Rat IgG2a, k 1/500 Flow cytometry 
eBioscience  
(25-5790-82) 
Mouse B220 eFlour450 Rat IgG2a, k 1/50 Flow cytometry 
eBioscience 
(558108) 
Mouse B220 
PE-Texas 
Red 
Rat IgG2a, k 1/500 Flow cytometry 
BD Pharmingen 
(551489) 
Mouse B220 FITC Rat IgG2a, k 1/100 Flow cytometry 
BD Pharmingen 
(553088) 
Mouse CD3 PerCP-Cy5.5 Hamster IgG1, k 1/200 Flow cytometry 
BD Pharmingen 
(551163) 
Mouse CD3 PE Hamster IgG1, k 1/200 Flow cytometry 
BD Pharmingen 
(553064) 
Mouse CD4 APC Rat IgG2a, k 1/300 Flow cytometry 
eBioscience 
(17-0042-82) 
Mouse CD4 PE Rat IgG2b,  k 1/500 Flow cytometry 
BioLegend 
(116006) 
Mouse CD4 PerCP Cy5.5 Rat IgG2a, k 1/300 Flow cytometry 
BD PharMingen 
(550954) 
Mouse CD11b PE Rat IgG2b,  k 1/1000 Flow cytometry 
eBioscience 
(12-0112-83) 
Mouse CD11c APC Rat IgG2b,  k 1/500 Flow cytometry 
eBioscience 
(17-0114-82) 
Mouse CD19 APC Rat IgG2a k 1/200 Flow cytometry 
BD PharMingen 
(550992) 
Mouse 
CD21/CD35 
APC Rat IgG2b,  k 1/100 Flow cytometry 
BD Pharmingen 
(558658) 
Mouse CD23 PE Rat IgG2a, k 1/200 Flow cytometry 
BD Pharmingen 
(553139) 
Mouse CD38 Pacific Blue Rat IgG2a, k 1/400 Flow cytometry BD Pharmingen 
Mouse CD38 
Alexa Fluor 
700  
Rat IgG2a, k 1/400 Flow cytometry 
eBioscience              
(56-0381-82) 
Mouse CD86 PE-Cy5 - 1/200 Flow cytometry eBioscience 
Mouse Fas 
(CD95) 
PE-Cy7 Hamster IgG 1/150 Flow cytometry 
BD Pharmingen 
(557653) 
Mouse CD138 APC Rat IgG2a, k 1/100 Flow cytometry 
BD Pharmingen 
(558626) 
Mouse PD-1 
(CD279) 
PE Rat IgG2b, k 1/100 
 
Flow cytometry 
 
BD Pharmingen 
(551892) 
Mouse 
CXCR4 
(CD184) 
FITC Rat IgG2b 1/100 Flow cytometry 
BD Pharmingen 
(551967) 
Mouse 
CXCR5 
Biotin Rat IgG2a, k 1/50 Flow cytometry 
BD Pharmingen 
(551960) 
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Specificity Conjugation Species/Isotype 
Final 
Dilution 
Experiment 
Company 
(Reference no.) 
Isotype control - Rat IgG2a, k 1/50 Flow cytometry - 
NP* PE - 1/2000 Flow cytometry  
Mouse IgD FITC Rat IgG2a, k 1/100 Immunofluorescence 
BD Pharmingen 
(553439) 
Mouse IgD APC Rat IgG2a, k 1/100 Immunofluorescence 
eBioscience  
17-5993-80 
Mouse CD73 - Rat IgG1 - Immunofluorescence 
eBioscience 
(14-0731-81) 
Mouse CD80 - Hamster IgG1 k 1/100 Immunofluorescence 
BD PharMingen 
(09601D) 
Mouse CD138 - Rat IgG2a, k 1/200 Immunofluorescence 
BD PharMingen 
 (553712) 
Mouse CD169 - Rat 1/100 Immunofluorescence 
AbD Serotech 
MCA947 
Mouse 
CXCR4 
(CD184) 
- Rat IgG2b 1/100 Immunofluorescence 
BD PharMingen 
(551852) 
Mouse Ki67 - Rabbit 1/400 Immunofluorescence 
Gift from J. 
Gerdes, Research 
Centre Borstel, 
Germany 
Rat Igs FITC Donkey 1/100 Immunofluorescence 
Jackson 
Immunoresearch  
(712-096-153) 
Rabbit Igs Cy3 Donkey 1/100 Immunofluorescence 
Jackson 
Immunoresearch  
(711-165-152) 
Hamster Ig Biotin Goat 1/100 Immunofluorescence Vector R0707 
FITC 
Alexafluor 
488 
Goat 1/100 Immunofluorescence 
Invitrogen 
(A11096) 
FITC 
Alexafluor 
488 
Rabbit 1/100 Immunofluorescence 
Invitrogen 
(A11090) 
Mouse IgM 
Alkaline 
Phosphatase 
 1/2000 ELISA AbD Serotech 
Mouse IgG 
Alkaline 
Phosphatase 
 1/1000 ELISA AbD Serotech 
Mouse IgG1 
Alkaline 
Phosphatase 
 1/1000 ELISA AbD Serotech 
Mouse IgG3 
Alkaline 
Phosphatase 
 1/1000 ELISA Southern Biotech 
 
Table 2.1 - List of antibodies used in this study (*NP is not itself an antibody, but is 
included for completeness). APC - Allophycocyanin , PE - Phycoerythrin, Cy3 – Cyanine 3. 
Cy5 – Cyanine 5, Cy7 - Cyanine 7, PerCP - Perdinin-chlorophyll protein, FITC - Fluorescein 
isothiocyanate. 
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3. RESULTS 
3.1 – Unimmunised DKO mice display increased T and B cell numbers in the 
spleen, but splenic architecture and cellular composition is largely unaffected 
in thymus-dependent responses  
 
First, we wanted to compare spleen sections of CCRL1/2 double knockout (DKO) 
mice with wild-type (WT) mice to look for any obvious histological defects. The T cell 
areas and B cell follicles were present and looked structurally similar in both mice, as 
shown by CD3 and IgD staining respectively (Fig.  3.1A). IgM+IgD- Marginal zone B 
cells were present in the marginal zones of the white pulp areas, and CD138+ plasma 
cells were also evident in the red pulp areas in both DKOs and WT controls. Both cell 
types appeared present in similar numbers. Mature red pulp macrophages express 
the surface molecule F4/80. The sections clearly show the presence of these 
macrophages in the DKO mice at a high density and clearly confined to the red pulp, 
similar to controls. Together these results suggest there is no clear defect in splenic 
microarchitecture, or deficiency in naive B cells, plasma cells, extrafollicular B cells, T 
cells or red pulp macrophages in the spleens of DKO mice. 
We next sought to examine the architecture of the spleen in the TD response of DKO 
mice. Mice were immunized with NP-CGG both i.p. and in the footpad and the 
response analysed at day 8. As expected, TZ and follicular structure was unaltered at 
this time point (Fig. 3.1B). The response to NP was evident in some mice from both 
the DKO and heterozygous (het) control groups. The reason some mice had not 
produced a response to NP by day 8 are unclear, but this is most likely due to 
problems with immunisations. Of those that responded, NP staining is denser in the 
LZ of germinal centres as this is where most FDCs hold immune complexes of 
antigen and specific antibodies that bind NP. Strong NP staining is also evident in 
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Unimmunised: 
Day 8 p.i.: 
WT: 
DKO: 
CD3/IgD IgM/IgD CD138/IgD F4/80/IgD 
Het: 
DKO: 
CD3/IgD NP/IgD CD138/IgD IgG/IgD 
B 
A 
TZ 
F 
TZ F 
RP 
RP 
MZ 
MZ 
F TZ 
TZ 
F 
RP 
RP 
GC 
LZ 
DZ 
Figure 3.1 - Comparison of splenic architecture in DKO mice and controls. 
A – Immunohistochemistry staining on sections from unimmunised DKO mice (n=4) and WT 
controls (n=2). Sections were stained for CD3, IgM, CD138 and F4/80 (blue) and IgD (brown). 
B - Immunohistochemistry staining on sections from mice day 8 post immunization (p.i) with 
the TD antigen NP-CGG. Staining was for CD3, NP, CD138 and IgG (blue) and IgD (brown). 
Heterozygous (Het) mice were used as controls (n=4) along with test DKO mice (n=2) 
Representative images are shown. Scale bars represent100μm in length. TZ – T cell zone; F – 
B cell follicle; RP – red pulp; MZ – marginal zone; GC – germinal centre; DZ – dark zone; LZ – 
light zone. 
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some red pulp areas, representing NP+ plasma cells. Furthermore, a few NP+IgD- 
cells can be seen around the GC, but still in the B cell follicle, most likely 
representing newly generated memory B cells. There were no noticeable differences 
in any localisation or density of any of these cell types in DKOs compared to controls.  
Plasma cells were present in both groups at day 8 p.i., although overall there may 
have been slightly more plasma cells in the DKO. However, as numbers of mice with 
successful immunisation leading to plasma cell generation were too low (n=2 for 
DKO), these results have not been deemed significant. Lastly, IgG was seen in 
similar amounts in the red pulp areas of DKO and het mice, indicating that class 
switching to IgG was present in the absence of CCRL1 and CCRL2. Overall, results 
indicate architecture and key cell types are very similar between DKO and control 
mice. 
When looking at the spleen sections as a whole it was noticed that some of the 
germinal centres in the DKO mice looked ‘rugged’ – i.e their edges were not clearly 
defined and merged into IgD+ areas of the B cell follicle (Fig. 3.1B). This would agree 
with the hypothesis discussed above that CCRL1 has a role in cellular positioning 
within the GC. Therefore, a blinded test was carried out where GCs were classed as 
rugged or non-rugged. However, the data obtained from these blinded counts do not 
show a relationship between irregular GCs and CCRL1/2 deficiency (Fig. 3.2). To 
give conclusive results this experiment should be repeated on a larger group of 
samples. Further, the development of a more objective method to measure whether a 
GC is rugged than the subjective microscopic decision used here would be helpful. 
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Alongside the histological analysis, flow cytometry was performed to look at any 
differences in cellular composition in the spleens of unimmunised DKO mice. The 
staining panel and gating strategy used allowed us to look at follicular and MZ B 
 
 
 
 
Figure 3.2 – Preliminary examination of GC ‘ruggedness’ in DKO and control mice d8 
p.i.  
Graph shows the median percentage of germinal centres  deemed rugged in DKO and het 
controls day 8 p.i. Data was collected blinded to the origin of the mice to remove bias (het 
n=4, DKO n=2). 
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cells, and the T cell population (Fig. 3.3A). MZ B cells express high levels of CD21 
and CD35 and low levels of CD21, as opposed to follicular B cells which express 
higher CD21 and IgD29.  
Results show a very slight increase in the percentage of overall B cells compared to 
controls, and a modest increase in T cell percentages (Figs. 3.3B, C). This is 
interesting as increased percentages of both B and T cells within the lymphocyte 
fraction would indicate other cell types (such as plasma cells or dendritic cells) were 
decreased correspondingly in DKO mice. Indeed, the ungated population within the 
lymphocyte gate represented a substantially smaller proportion of lymphocytes in 
DKO mice (data not shown). In absolute numbers, the increase in B cells and T cells 
is even more robust (Fig. 3.3D). Within the B cell subset, follicular B cells were 
increased in percentage and number in DKO mice, whereas MZ B cells showed 
minimal change. Thus, it appears DKO mice have an increased representation of B 
and T cells in the spleen. 
Spleens from mice immunised with NP-CGG were also analysed by flow cytometry. 
Before maceration and staining, spleens were weighed. Interestingly, DKO spleens 
weighed slightly less on average than control spleens (Fig. 3.4A). B cells that 
responded to NP were gated on first, and a combination of anti-CD38, anti-Fas, anti-
CD86 and anti-CXCR4 antibodies allowed us to identify GC B cell populations. An 
anti-CD138 antibody was used to identify plasma cells (for gating strategy see figure 
3.4B)30. It is worth noting that CD38 staining was unsuccessful in this instance, so 
GC B cells were selected on Fas expression alone. Although memory B cells will also 
be included in this gate, the majority will still be GC B cells. 
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Figure 3.3 – Analysis of key splenic cell types in unimmunised DKO mice. 
A – Gating strategy used. Live lymphocytes were first gated on according to their forward and 
side scatter properties. Singlet lymphocytes were then gated on before gates were set on 
CD3
high
B220
low
 cells (T cells) and B220
hi
CD3
lo
 cells (B cells). Within the B cell gate, IgD
hi
 cells 
were considered follicular B cells while CD21/CD35
hi
 CD23
lo
 cells within the IgM
hi
 gate were 
considered marginal zone B cells. Arrows indicate direction of gating. B – Representative IgD 
vs IgM plots from DKO and Het control. C – Comparison of key cell types in DKO (red circles) 
and Het mice (black circles). Data represented as percentage of singlet lymphocytes (C) and 
absolute cell number (D). Lines represent median values. Sample sizes: DKO = 3, Het = 2. 
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Figure 3.4 – Flow cytometric analysis of key cellular populations in the TD B cell 
response in the spleen day 8 p.i. 
A – Comparison of spleen weights between DKO and Het. B – Gating strategy used. Live 
lymphocytes gated on (not shown), then NP
+
 responder cells. From here CD138
+
 plasma 
cells , and B220
+
 total responder B cell percentages were analysed (far right gates). 
Fas
hi
CD38
lo
 cells were gated on as total GC B cells, and finally CXCR4 and CD86 were used 
to distinguish DZ and LZ B cells (note gating strategy is identical to that used for lymph node 
[figure 3.8] and example shown is from lymph node sample in order to show a clear GC B 
cell population). Arrows represent gating direction. C – Percentage of singlet lymphocytes 
(C) and absolute number of cell (D) comparison between DKO and het mice. Lines represent 
medians, red – DKO, black – het. Sample sizes: DKO = 3, Het = 4. 
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Despite a reduced median weight of the DKO spleens, the numbers of B cells that 
responded to NP-CGG were unaffected in DKO mice (Fig 3.4D). Similarly, GC B 
cells and plasma cell numbers were unaltered. There were also no apparent 
differences in these subsets as a percentage of lymphocytes, although there was a 
slight trend of increased GC B cell and LZ B cell percentages in the DKO mice (Fig. 
3.4C). This could suggest that DKO mice produce more GC B cells in a TD response 
by day 8 than het controls, although histology shows no obvious difference in 
germinal centre sizes or IgG class switching (Fig. 3.1A). However, more data is 
needed for a convincing conclusion to be drawn.  
To test whether CCRL1 has a role controlling cellular trafficking of T cells in the GC, 
we also carried out a stain for TFH cells – involved in selection of centrocytes in the 
LZ (see section 1.2.1). The CXCR5 antibody was biotinylated, requiring a second 
step addition of streptavidin conjugated toPE-Cy7. To control for this staining, both 
biotinylated isotype control antibodies, and streptavidin PE-Cy7 alone were used. 
Unfortunately minimal expression of CXCR5 was observed above background (Fig. 
3.5B) indicating the staining procedure had failed. An analysis of CD4+ cells showed 
no difference between DKO and het mice (Fig. 3.5A, C). This backs up the histology 
results seen previously where T cell numbers appear similar in both groups. 
Overall, no apparent differences were seen in the splenic organization of DKO mice, 
both immunised and un-immunised. However, in terms of cellular composition, 
modest increases in B and T cells can be seen in the unimmunised DKO mice. At 
day 8 p.i. with NP-CGG, spleens of DKO mice appear slightly reduced in mass 
compared to controls (despite no B or T cell deficiency),  and it is possible there are 
small increases in GC B cell percentages compared to controls. This could indicate a  
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Figure 3.5 – T follicular helper stain on splenocytes day 8 p.i. 
A – Gating strategy. Singlet lymphocytes were gated on (not shown) followed by CD4
+
 cells and in 
this gate PD-1
+
CXCR5
+
 cells represented T
FH
 cells. B – Controls for CXCR5 PE-Cy7 stain. 
Frequency histograms show signal intensity in the PE-Cy7 channel: Green – biotinylated CXCR5 
antibody, blue – biotinylated isotype control antibody and red no primary antibody. All samples had 
the anti-streptavidin PE-Cy7 antibody added after an incubation period. C – Comparison of CD4
+
 T 
cells in DKO and het spleens as a percentage of lymphocytes. 
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slightly faster induction of the GC response, but results must be interpreted with 
caution due to small sample sizes and only modest differences in magnitude. 
3.2 – Lymph node microarchitecture and cellular composition is unaltered in 
DKO LNs, but lymphocyte cellularity is reduced in the TD response and at rest 
 
The next logical step was to look for any differences in lymph node populations. 
Overall B and T cell populations were examined. Mature B cells were defined as 
IgD+, whereas the IgMhi fraction contained a mixture of monocytoid B cells (lymph 
node equivalents of MZ B cells) and transitional 1 and 2 B cells31, 32. Results show no 
differences in percentage of lymphocytes in either the mesenteric or inguinal lymph 
nodes of DKO mice when compared to het controls (Fig. 3.6A, B & C). Interestingly 
though, IgMhi B cells, mature B cells and T cells were all reduced in number in DKO 
mice, especially in the B cell compartment (Fig. 3.6D, E). 
On day 8 post immunisation with TD antigen NP-CGG, popliteal lymph nodes (the 
lymph nodes draining the immunised foot) were cut and their histology analysed by 
immunohistochemistry. As seen in the spleen, TZs and B cell follicles were unaltered 
(CD3 and IgD staining respectively) (Fig. 3.7A). The presence of IgG+ B cells in the 
lymph node medulla in DKO mice indicates class switching is occurring, and F4/80+ 
macrophages are also present only in the medullary regions of both DKO mice and 
controls. Of those mice that responded to the antigen, dense expression of NP-
specific plasma cells was seen in the medullas of LNs (Fig. 3.7A, B). NP-binding was 
also detected in the TZ (presumably due to diffusing antibody, or antibody bound to 
the reticular cells of the stroma) and also in GCs. Similar to spleen, some NP+ cells 
were seen around GCs in the follicles, most likely representing exiting memory B 
cells. DKO and het mice both displayed all these same expression patterns. These  
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Figure 3.6 – Analysis of the B cell response in the lymph nodes of unimmunised DKO 
mice. 
A – Gating strategy – within the singlet lymphocyte gate, CD3
+
 cells (T cells) and B220
+
 cells 
(B cells) were analysed. In the B cell gate, IgM and IgD were used to distinguish B cell types 
further. B – Percentages of B cells, B cell subtypes and T cells in the inguinal lymph node 
(iLN – B) and the mesenteric lymph node (mLN – C). D – Absolute cell numbers of the same 
cell types in iLN (D) and mLN (E). Lines represent median values. DKO mice (n=4) displayed 
in red, Het mice (n=2) displayed in black. 
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Het: 
DKO: 
CD3/IgD NP/IgD IgG/IgD F4/80/IgD 
Het: NP/IgD 
  
DKO: NP/IgD 
  
B 
GC 
Figure 3.7 – Lymph node architecture in DKO and het control mice. 
A – Immunohistochemistry staining of lymph node sections from DKO and het mice immunised 
with NP-CGG (day 8 p.i.). Sections were stained for CD3, NP, IgG and F4/80 (blue) and IgD 
(brown). B – Whole representative lymph node images of DKO and het samples stained for NP 
and IgD. 4 het mice and 3 DKOs were used in this experiment. 
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data revealed apparently normal GC formation and class switching to IgG occur in 
the LN response to TD antigens in CCRL1/CCRL2 deficient mice. 
Interestingly, popliteal lymph nodes from DKO mice were physically smaller and 
weighed less than control equivalents day 8 p.i. with NP-CGG (Fig. 3.8A, B). 
Consistent with this observation, there were on average less than half the numbers of 
NP-responder B cells in DKO mice compared to controls (Fig. 3.8E). It followed that 
NP+ GC B cells (including both DZ and LZ B cells) and NP+ plasma cells were also 
reduced in numbers the knockout (Figs. 3.8C, E). However, as in the unimmunised 
mice, there were no differences in percentages of NP+ responder B cells or their 
subtypes in DKO mice. 
Together these results show no change in the composition of the lymph node, 
initiating the germinal centre reaction, or undergoing class switching to IgG in DKO 
mice. However, both pre- and post-immunisation with NP-CGG, B and T cell 
numbers are reduced. 
3.3 – Antibody titres and antibody affinity is unaltered in DKO mice in the TD 
response 
We next wanted to know whether antibody titres and antibody affinity are affected in 
DKO mice. ELISAs were carried out on serum from unimmunised and immunised 
mice (day 8 post NP-CGG). Serum was diluted across the ELISA plate and 
absorbance readings used to calculate relative titres for each mouse (Fig. 3.9A). 
Relative titres of IgM and IgG day 8 p.i. were no different between DKO mice and 
heterozygous controls, while before immunization antibody titres were undetectable 
(Fig. 3.9B). Total NP-specific IgG1 was detected with NP15, while higher affinity NP-
specific IgG1 was detected with NP2 as only very high affinity IgG would be able to  
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Figure 3.8 – Analysis of the B cell response in the lymph nodes of DKO mice d8 p.i. 
A – Photograph comparing size of popliteal lymph nodes of DKO to het controls (red underline 
shows a LN from a CCRL1-/- CCRL2wt/wt that was originally mistyped as a DKO and 
therefore excluded from further analysis). B – Comparison of popliteal lymph node weights 
between two groups. C - Representative GC B cell (top panel) and plasma cell (bottom panel) 
plots for het and DKO mice. D – Comparison of B cell subtypes in DKOs and controls 
represented as percentage of lymphocytes (D) and cell numbers (E) by flow cytometry. Lines 
represent median values. DKO mice (n=3) displayed in red, Het mice (n=4) displayed in black. 
37 
 
  
IgM example standard curve
100 1000 10000
0
1
2
3
4
d8het1
d8het2
d8het3
d8het4
d8KO1
d8KO2
d8KO3
d8KO4
d0het1
d0het2
d0KO1
d0KO2
d0KO3
d0KO4
dilution
A
b
s
o
rb
a
n
c
e
A 
B 
C 
NP-Specific IgM
0 8
102
103
104
Het
KO
<30
Days post Immunisation
R
e
la
ti
v
e
 T
it
re
NP-Specific IgG
0 8
102
103
104
Het
KO
<30
Days post Immunisation
R
e
la
ti
v
e
 T
it
re
NP-Specific Total IgG1
0 8
102
103
104
Het
KO
<30
Days post Immunisation
R
e
la
ti
v
e
 T
it
re
NP-Specific high affinity IgG1
0 8
102
103
104
Het
KO
<30
Days post Immunisation
R
e
la
ti
v
e
 T
it
re
Relative affinity - IgG1 day 8 p.i.
H
et
D
K
O
0.01
0.1
1
10
DKO
Het
R
e
la
ti
v
e
 a
ff
in
it
y
 (
N
P
2
/N
P
1
5
)
Figure 3.9 – Antibody titres and affinity in DKO mice and controls, unimmunised and day 8 
p.i. with NP-CGG. 
A – Example standard curve (IgM) of absorbance changing with serum dilution displaying how the 
relative antibody titres were calculated. Black horizontal line represents chosen absorbance 
threshold. Red - DKO d8 p.i., black – Het D8 p.i., pink – DKO unimmunised, grey – het 
unimmunised. B – Relative titres for NP-specific IgM, -IgG, -IgG1, and IgG1 of high affinity in DKO 
and control mice at day 0 (unimmunised) and day 8 post NP-CGG immunisation. C – Relative 
affinity of IgG1 antibody in DKO and control mice day 8 p.i. Calculated by IgG1 high affinity 
relative titre/ total NP-specific IgG1. Lines indicate median values, red =DKO (n=3) and black = 
het (n=4). 
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compete for the two available binding sites. No differences in these antibody titres 
were detected relative to controls. Lastly, relative affinity of IgG1 was calculated (Fig. 
3.9C). This too displayed no difference between DKO mice and hets. The combined 
results therefore suggest no difference in antibody titres or in antibody affinity at day 
8 in the TD response, despite reduced NP-specific B cell numbers in the draining 
lymph node. 
3.4 – Preliminary immunofluorescence staining reveals normal subcapsular 
sinus and medullary macrophage location is normal, and lymph node 
proliferation patterns are unaltered 
 
In order to see if any other cell types were altered in DKO lymph nodes, preliminary 
immunofluorescence staining was carried out. We initially wanted to investigate if 
there were any differences in memory B cell numbers or location by using the 
combined memory markers CD80 and CD7333. Unfortunately, a titration of CD73 was 
unsuccessful and CD80 staining also did not reveal any significant expression above 
background in the LN (data not shown). Due to time constrictions these experiments 
were not taken further. 
We also looked at plasma cell location in the popliteal lymph nodes (day 8 p.i. with 
NP-CGG) using CD138. Plasma cell staining was seen in the medullas of both mice 
(Fig. 3.10). The representative pictures show more intense CD138 staining in the 
het, but small sample numbers and previous data suggest this is not a real 
difference. The pictures also show proliferation is occurring throughout both lymph 
nodes, but mostly in germinal centres. Lastly, CD169 staining revealed that 
subcapsular sinus macrophages and medullary sinus macrophages were present in 
both mice34. 
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Het: Ki67/CD138 DKO: IgD/CD138 
DKO: IgD/CD169 Het: Ki67/CD169 
GC 
Figure 3.10 – Immunofluorescence staining of whole lymph node sections. 
Lymph nodes from DKO and Het mice stained with the following antibodies: anti-IgD -APC 
and anti-Ki67 Cy-3, anti-CD138 -FITC, and anti-CD169-FITC. Lymph nodes used are day 
8 p.i. with NP-CGG (DKO – n=3, Het – n=2). 
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3.5 – Higher antibody titres are seen in the TI-2 response of DKO mice 
To further unravel defects in the B cell response in DKO mice, we next analysed TI-2 
responses using the antigen NP-Ficoll. On day 5 of the response, splenocytes were 
analysed by flow cytometry and the antibody responses in the serum were visualised 
using ELISAs. 
Neither responder cells nor plasma cells were any different in DKO mice compared to 
WT controls when looked at by percentage of lymphocytes or numbers (Figs. 3.11C, 
D). However, the weight of the whole spleen appeared increased in DKO mice 
(although the range was fairly large in WT controls) (Fig. 3.11D). ELISA results 
showed that NP specific IgM and IgG3 titres were greater in DKOs (Fig. 3.11E). IgM 
showed a more prominent increase than IgG3 titres, but neither were quite 
statistically significant (p=0.1143 and 0.2 for IgM and IgG3 comparisons 
respectively). Therefore although there are no differences in the numbers of plasma 
cells in the spleen, ELISA results indicate class switching takes place, and antibody 
titres are higher in DKO mice.  This suggests that more antibody per plasma cell was 
being produced, or that antibody production in the DKO plasma cells sets in earlier. 
Also, other plasma cell populations, such as bone marrow plasma cells, were not 
analysed and could be help explain these observations.  
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Figure 3.11 – TI-2 responses in DKO mice. 
A – Gating strategy used. NP
+
 B cells (NP
+
B220
+
) were gated on and within this population 
CD138
+
 plasma cells were analysed (live lymphocyte and singlet gates not shown). B – 
Representative plots from WT and DKO in the B220 responder cell gate. C – Spleen weights 
in the TI-2 response day 5 p.i. D - Comparison of NP-responder B cells and NP
+
 Plasma cells 
in DKO and WT control mice day 5post NP-Ficoll immunisation by percentage of 
lymphocytes (left) and numbers (right). E – Relative titres of NP specific IgM and IgG3 as 
assayed by ELISAs day 5 post NP-Ficoll immunisation. Lines represent median values, red = 
DKO, black = WT control (both n=4). 
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4. DISCUSSION 
The exact roles of the atypical chemokine receptors CCRL1 and CCRL2 in the B cell 
response are unclear. CCRL1 binds to and degrades CCR7 ligands CCL19 and 
CCL21, and our lab has shown CCRL1 is expressed in the GC [Laura Ibanez – 
unpublished data]. Therefore it has been proposed CCRL1 may be involved in GC 
homeostasis – by degrading CCL19 and CCL21, CCRL1 could help keep unwanted 
T cells out of the GC and permit the egress of plasma cells and memory cells. This 
hypothesis is currently under investigation. In humans CCRL1 has been shown to 
bind CXCL13, implying a further role in the GC. Whether this is also the case in mice 
is so far unknown. 
 
The binding partners for CCRL2 are less established: CCL5 and Chemerin have 
been proposed, along with CCL19. Data from our lab suggests CCRL2 is expressed 
primarily on plasma cells within the B cell compartment and CCRL2-deficient mice 
produce more plasma cells and antigen-specific antibody in the TI-2 response. 
Preliminary results indicate this may be due to increased plasma cell proliferation. 
There is no major difference in antibody titres in TD responses [Sarah Cook – 
personal communication]. 
 
As CCRL1 and CCRL2 arose by gene duplication, their function may be similar. 
Therefore it was thought that the lack of a clear phenotype in either of the single 
knockout mouse strains may be due to a degree of compensation. Thus, a double 
CCRL1 CCRL2 knockout strain was produced to investigate the phenotype of mice 
deficient in both receptors. 
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Overall, a minor phenotype was seen in the DKO mice, but a few interesting 
observations were made. Unimmunised mice had normal TZs and B cell follicles, 
marginal zones and red pulp areas in the spleen (Fig. 3.1A). However, there were 
greater numbers of B and T cells in unimmunised DKO mice spleens compared to 
controls, and within the lymphocyte population both T and B cells were also 
increased in percentage (Fig. 3.3). This was interesting as it suggested another cell 
type/other cell types were correspondingly decreased. Although results must be 
interpreted with caution due to small sample numbers and only modest differences in 
B cell percentages, further investigation is warranted. When the ungated population 
was analysed this expected decrease was seen, suggesting plasma cells (which can 
show reduced B220 expression as they mature), DCs or NK cell numbers could be 
affected. Plasma cells are a possible candidate given the proposed B-cell specific 
roles of CCRL1 and CCRL2. However the lymphocyte gate used was quite large, so 
it may also be other non-lymphocyte leukocytes that are behind the decrease. 
Interestingly, Heinzel et al. showed reduced entry of DC into skin draining lymph 
nodes in CCRL1-deficient mice, but no differences were reported in the spleens of 
these mice17. A difference in DC homing to the spleen in CCRL1-deficient mice could 
explain our findings. Staining with additional markers for plasma cells, DCs and 
additional leukocytes would help explain these results. 
 
Histologically, there were no obvious changes in spleens of DKO mice that were 
immunised with the TD antigen NP-CGG. GCs were present in DKO mice and 
plasma cells were produced (Fig. 3.1B). Class switching to IgG was also evident in 
the knockout mice. Plasma cell presence as shown by CD138 staining was not as 
dense as the NP staining suggests (Fig. 3.1B – middle panels), but it was 
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suggested this is most likely due to differences in primary antibody affinities. GCs 
were also suggested to be irregular/rugged in DKO mice. A preliminary blinded 
quantitative analysis using a subjective measure for ruggedness did not produce 
substantially different results (Fig. 3.2). However, a more objective measure for 
spatial changes in GC architecture, and larger sample sizes, may change this picture 
and this needs to be taken further. In both groups combined only three mice had 
more than 10 GCs in the spleen sections, so larger sample sizes would be needed. 
The classification of GCs as rugged would also need to be reviewed. A more 
objective way to measure ruggedness could be the percentage of IgD+ (brown) cells 
that were within the boundary of the NP+ (blue) GC. Also, staining with the GC 
marker peanut agglutinin (PNA) would allow easier classification of ruggedness. If 
DKO GCs were found to be more rugged, this would make sense within the proposed 
model of CCRL1 maintaining GC homeostasis and preventing influx of unwanted 
cells, possibly by scavenging CXCL13, or by producing a strong CCL19 sink in the 
GC. 
 
The only observed differences in the TD response in the spleen were a slight 
decrease in spleen weight and a slight increase in percentage of GC B cells in DKO 
mice (Fig. 3.4). The decrease in spleen weight did not result in any decreases in 
absolute number of the cell types investigated. The reasons for this are unknown, but 
it is worth pointing out the average number of responder B cells would be lower if it 
were not for one het mouse with a very low number (Fig. 3.4D). The increase in GC 
B cells was very slight (Fig. 3.4C), but if confirmed would also support a role of 
CCRL1 in the GC. If CCRL1 is able to bind and degrade CXCL13 in mice, a 
deficiency in this receptor would cause an increase in available CXCL13, so more B 
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cells would be attracted to the GC. However, only a tentative conclusion can be 
made with these results as the GC response in the spleen may not be developed 
enough at day 8 p.i., and there were difficulties in distinguishing DZ from LZ B cells 
by flow cytometry. Further repeats at day 8 and a further time point such as day 10 
p.i. would allow us to either confirm or reject these trends statistically. 
 
In the LNs, both before and after TD antigen administration, there was a decrease in 
B and T cell numbers (Fig. 3.6; 3.8). There was also a corresponding decrease in 
weight and size of popliteal LNs at day 8 p.i.. This could imply a role for CCRL1 or 
CCRL2 in recruiting cells to LNs, though as with other experiments more repeats are 
needed. This indication would be counter intuitive as CCRL1 is known to degrade 
CCR7 ligands and so if anything, cellularity of LNs would be expected to increase 
when this receptor is absent. There may therefore be additional interactions or 
functions of CCRL1 and CCRL2. Comerford et al. also noticed decrease lymph node 
cellularity in CCRL1-deficient mice, suggesting lack of CCRL1 is responsible for this 
phenomenon in our study16. Interestingly, our LN results are different to those in the 
spleen, highlighting the differences in the workings of these two SLOs. The 
composition of cells present in the LN is not altered. 
Histology of DKO mice appears normal, indicating dense NP staining and evidence 
of class switching in those mice that responded (Fig. 3.7). No GCs were seen in the 
example het LN, but this is most likely due to poor section quality. In both LN and 
spleen NP+ cells were seen around the edges of GCs, likely representing memory 
cells. Data from our lab indicates that memory cells exit the germinal centre and 
move towards the subcapsular sinus through the follicle [Kai Toellner – personal 
communication].  We attempted to see if memory B cell chemotaxis was affected in 
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DKO mice by doing immunofluorescence staining for memory markers CD80 and 
CD73. Unfortunately staining was unsuccessful and must be repeated in future 
experiments. If the equipment were available, intravital microscopy could also be 
used to track memory cell migration in real time. Our immunofluorescence staining 
here also revealed proliferation was occurring normally in DKO LNs, and CD169+ 
macrophages were present in a distinct pattern around the perimeter of the LN (the 
subcapsular sinus [Fig. 3.10]). This is very similar to immunofluorescence results 
shown by Satpathy et al35. Lastly, in the context of the TD response, ELISAs 
revealed no difference in antibody titres or IgG1 affinity between DKO and het mice 
(Fig. 3.9). 
Within the TI-2 response, no differences were seen in responder B cells or plasma 
cell compared to controls (Fig. 3.11). This is despite an apparent larger weight of 
DKO spleens. The controls used in these final experiments were WT, not het due to 
lack of het control mice. While het mice are bred at our own facility, WT mice are 
bought in from a commercial breeder. This commercial facility is likely to be cleaner 
than our specific pathogen free facility, and this could explain the slight splenomegaly 
in the DKO mice. This was not a factor in previous experiments when het littermates 
were used. Even though responder B cells were not increased in DKOs, and overall 
lymphocytes were not increased (data not shown) it may have been T cells were 
increased correspondingly (not analysed). Finally, higher titres of NP-specific IgM 
and IgG3 were produced by plasma cells from DKO mice (Fig. 3.11E). This is in line 
with data from CCRL2-/- mice [Sarah Cook – personal communication]. However, no 
corresponding increase in plasma cells conflicts with our labs previous data. These 
results therefore indicate that plasma cells in CCRL1/CCRL2 deficient mice are 
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producing more antibody per cell and that additional CCRL1 deficiency may 
counteract the decrease in plasma cell numbers seen in CCRL2-/- mice alone. 
In conclusion, this study provides some valuable preliminary data on the roles of 
these receptors in antibody responses, but in many cases further supporting data are 
needed. Key B cell types were present in the DKO in their expected locations. DKO 
spleen analysis showed increases in B and T cells before immunisation but no 
difference in these cells after immunisation with NP-CGG. Conversely, LN B cell 
populations were decreased both before and after NP-CGG immunisation. The TD 
response revealed no difference in NP-specific antibody titres, whereas both IgM and 
IgG3 were increased in the TI-2 response. Although no mechanism can be inferred 
from this data, interesting avenues of further study include looking into GC shape 
(ruggedness), increases in GC B cell populations and memory cell chemotaxis in 
these DKO mice. It appears that the effects of these two receptors are disparate, 
rather than similar as originally thought, and there appear to be no compensatory 
overlapping functions that would have been revealed in the DKO mice. CCRL1 
deficiency is probably responsible for the potential rugedness of GCs, while CCRL2 
is more likely behind the increased antibody titres in the TI-2 response (supported by 
recent data from our lab). Therefore the mouse model used in this study may well be 
complicating the picture rather than simplifying it as the effects of deficiencies in both 
receptors are compounded. Continuing the studies of single CCRL1 and CCRL2 
knockout mice are the obvious way to address this issue, and could be vital in fully 
understanding B cell migration and function in SLOs, and thus in modifying the B cell 
response. 
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ABSTRACT: 
Adoptive transfer T cell therapy involves the ex vivo expansion of T cells followed by 
reinfusion to a patient to treat disease. These T cells can be engineered to express 
chimeric antigen receptors (CARs) that combine MHC-independent antigen 
recognition with T cell effector functions. Second generation CARs encompass a 
costimulatory endodomain to enhance T cell activation and survival. So far, there 
have been conflicting reports concerning whether CD28-containing CARs or 4-1BB-
containing CARs provide T cells with favourable responses. Therefore, this 
investigation aimed to compare these two constructs for the in vitro functional T cell 
output they provide. T cells were retrovirally transduced with either construct, both of 
which recognise CLEC14A – a tumour vasculature antigen, and their transduction 
efficiencies, proliferation and IFN-γ production analysed. CD28-CAR+ T cells showed 
slightly enhanced transduction efficiencies when compared to 4-1BB-CAR+ T cells. 
Furthermore, CD28-CAR+ T cells produced far superior IFN-γ and degranulation 
responses, but 4-1BB-CAR+ T cells showed a greater resistance to apoptosis. 
Together, these data suggest the CD28-CAR is favourable, showing greater IFN-γ 
and cytotoxic responses, despite the greater propensity for apoptosis. Further work 
will allow an optimum CAR to be designed for future use in the treatment of human 
cancers.
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1. INTRODUCTION 
1.1 - Cancer Immunoediting 
It is well established that the immune response influences the development of many 
cancer types.  Effector leukocytes have the ability to recognize tumour-specific 
antigens (TSAs) and eliminate the tumour cells before cancer becomes apparent. 
This process is referred to as cancer immunosurveillance1. However, cancer still 
develops in immunocompetent individuals, and there is strong evidence showing that 
the same process can also promote cancer growth. Eliminating the most 
immunogenic cancer cells may result in the survival of the least immunogenic 
variants, potentially allowing the establishment of more resilient cancer cells. 
Evidence for this comes from studies that demonstrate tumours transferred from 
immunocompromised mice into wild-type mice are rejected more readily than 
tumours transplanted from wild-type origin2-5. Taking the actions of the immune 
system on both preventing and promoting cancer growth into account, the hypothesis 
of cancer immunoediting was proposed5. Cancer immunoediting can be broken down 
into three distinct phases – the elimination phase, the equilibrium phase, and the 
escape phase5.  
 The elimination phase is synonymous with the term cancer immunosurveillance; 
describing the destruction of tumour cells and thus preventing malignancy1. This is 
not a new concept; many studies have described an increased susceptibility of 
immunocompromised animals to a variety of cancers in various mouse models of 
tumour induction. Likewise in human studies, higher frequencies of malignancies are 
seen in immunodeficient individuals. This includes patients with acquired 
immunodeficiency syndrome or on immunosuppressive treatments1. 
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Both the innate and adaptive arms of the immune system are involved in the anti-
cancer response. The response begins when innate immune cells such as natural 
killer (NK) cells, Natural killer T (NKT) cells, γδ T cells and macrophages are 
recruited by proinflammatory cytokines and chemokines that either originate from the 
tumour itself, or are released due to the local destruction caused by characteristic 
stromal remodelling. Recognition of the tumour then occurs, and the cytokine 
interferon-gamma (IFN-γ) is produced. This in turn induces chemokine-mediated 
recruitment of more innate immune cells, and by a variety of local positive feedback 
mechanisms, the amount of IFN-γ produced is amplified. IFN-γ stops tumour growth 
by inhibiting both angiogenesis and proliferation, and also causes apoptosis5. 
Furthermore, IFN-γ induces TNF-related apoptosis-inducing ligand- (TRAIL) 
dependent tumour cell killing by macrophages, and perforin-dependent killing by NK 
cells5. The tumour antigens that are released as a result of tumour cell death are 
taken up by activated dendritic cells (DCs). These DCs migrate to the draining lymph 
node and present their antigen to naïve CD4+ and CD8+ T cells. Tumour-specific T 
cells are activated in turn, and migrate to the tumour site. Here they recognise 
tumour-associated antigens (TAAs) and cause destruction of the tumour cells as well 
as amplifying the whole process through the release of more IFN-γ5 (process 
reviewed in more detail in REF 5). 
Despite the efficacy of the immune response against cancer, the least immunogenic 
tumour cells may survive, allowing for their persistence. This is because the immune 
attack exerts a strong selection pressure on the heterogeneous tumour population, 
resulting in the survival of only those mutant cells that can withstand the response5. 
These variants enter the equilibrium phase where tumour cells are still present, but 
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net outgrowth is prevented by the immune system. This phase can continue 
asymptomatically for the lifetime of a patient1. 
The final stage of cancer immunoediting is termed the escape phase. This occurs 
when tumour variants acquire mutations that provide them with the means to escape 
recognition completely, or with resistance to immune attack. It is at this phase when 
tumours become clinically detectable5. Tumour cells can circumvent the immune 
response in a great many ways, including the downregulation of the major 
histocompatibility complex (MHC) molecules required for T cell recognition, and the 
upregulation of anti-apoptotic molecules such as B-cell lymphoma-extra large (Bcl-
XL). Tumour cells can also acquire mutations leading to the expression of molecules 
that directly kill T cells, for example programmed cell death ligand 1 (PD-L1) or Fas 
ligand. On top of this, tumour cells can secrete a variety of anti-inflammatory 
cytokines and other factors that dampen the immune response and recruit regulatory 
cells such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells 
(TREGs) to the tumour site, which in turn inhibit the immune response further
1 
(Reviewed in REF 1). 
1.2 - The role of T cells in targeting cancers 
T cells have shown to be vital in the recognition and elimination of various cancers. 
Mice deficient for the recombinase activating gene-2 (RAG2), lack T cells, and 
studies have shown these mice are more susceptible to both chemically induced and 
spontaneous tumours when compared to wild type mice2. Furthermore, in mice 
lacking αβ T cells or γδ T cells, susceptibility to chemically induced and injected 
tumours is increased7 . Both CD8+ (cytotoxic) and CD4+ (helper) T cells have roles in 
this tumour cell rejection. CD8+ T cells can degranulate, releasing cytotoxic 
mediators, following recognition of TAAs that are displayed on MHC class I 
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molecules on the tumour cell surface, but can also contribute to tumour cell killing by 
IFN-γ production. CD4+ T helper 1 (TH1) cells promote CD8
+ T cell recruitment, and 
also provide IL-2 signals to facilitate CD8+ T cell survival, as well as producing IFN-γ 
and tumour necrosis factor-α (TNF-α). Furthermore, they can enhance the activation 
of DCs via CD40-CD40L interactions, thus allowing the priming of more CD8+ T 
cells8, 9. More recently, studies have shown some CD4+ T cells can develop cytotoxic 
activity and kill tumour cell targets directly10, 11. 
 However, as eluded to above, T cells do not always succeed at destroying the 
cancerous cells completely, allowing for immune evasion and outgrowth. This may be 
because many TAAs are derived from self-proteins that are aberrantly expressed, 
and so central and peripheral tolerance mechanisms that prevent targeting of self-
tissues only allow T cells with low T cell avidity for these antigens to survive and 
respond12. Also, tumour infiltrating T cells may undergo T cell exhaustion, and the 
tumour cells may acquire mutations that allow for downregulation of antigen 
presentation, T cell suppression, and T cell apoptosis8. Therefore methods by which 
the T cell response to cancers can be enhanced are needed. 
1.3 - Adoptive T cell transfer therapy for the treatment of cancers 
In order to utilise and enhance the natural immune response against cancers, 
immunologists have turned to adoptive T cell transfer therapies. This process 
involves the isolation of T cells from a patient and their expansion in culture. The 
cells are then reinfused back to the patient in order to treat disease8, 12. Isolated T 
cells are often cultured with IL-2 to facilitate their expansion, before those T cells with 
the desired specificities and differentiation states can be selected and transferred 
back to the patient8. Host lymphodepletion can be carried out to improve transferred 
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T cell survival and engraftment, and co-administration regimens of cytokines such as 
IL-2, IL-15 or IL-7 have been explored to enhance the anti-tumour response13. 
This treatment has distinct advantages over more conventional treatments. It is 
minimally invasive unlike surgery, and should be more controlled and specific when 
compared to traditional chemotherapy options based on targeting all dividing cells. 
Furthermore, evidence suggests that adoptive T cell transfer therapy is much more 
efficacious than therapeutic vaccines in achieving complete tumour regression8. 
Isolated T cells can also be engineered to express receptors of desired specificities. 
This is usually done by retroviral or lentiviral transduction techniques whereby a viral 
carrier transports the transgene of interest into the T cell and causes its integration 
into the genome – resulting in stable expression. Two main types of engineered T 
cells have been explored – those expressing αβ T cell receptors (TCRs); or those 
expressing CARs (chimeric antigen receptors) 12. 
1.4 - Chimeric antigen receptors (CARs) 
1.4.1 - Introduction to CARs 
CARs are comprised of an intracellular TCR signalling domain fused to the antigen 
binding domain of an antibody12. CARs combine the potent effector functions of T 
cells with the high antigen affinity of antibodies, making for a robust and powerful 
anti-tumour response. First generation CARs consist of extracellular variable heavy 
and light chain fragments connected by a linker sequence, a transmembrane domain, 
and the intracellular CD3ζ signalling domain of the TCR complex. Second generation 
CARs also include a costimulatory endodomain fused to the CD3ζ, while third 
generation CARs contain two costimulatory endodomains (Fig 1.1). These domains 
are derived from the costimulatory molecules CD28, 4-1BB (CD137) or OX40  
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Figure 2.1– First, second and third generation CAR constructs.  
First generation CARs are comprised of antibody variable light and heavy chain domains, 
connected by a linker sequence, a hinge domain, a transmembrane domain and an 
intracellular CD3ζ domain.  The extracellular antibody domain (single chain variable 
fragment – scFv) provides high affinity, non-MHC restricted antigen recognition, while the 
hinge domain allows for flexibility of this binding region. The CD3ζ signalling domain 
mediates the transformation of antigen recognition into signalling pathways and T cell 
effector function. Second generation CARs also incorporate a costimulatory endodomain, 
such as 4-1BB or CD28 that increase T cell activation and survival.  More recently, third 
generation CARs have been developed that include two costimulatory endodomains. VH – 
variable heavy chain, VL – variable light chain, ζ – CD3ζ domain. Figure taken from  REF 
13. 
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(CD134). Studies have shown that the inclusion of costimulatory endodomains 
results in greatly enhanced T cell survival and expansion, and prevents T cells 
undergoing functional unresponsiveness (anergy), when compared to first generation 
CARs in both mouse and human studies13-20. 
1.4.2 - Benefits and drawbacks of CARs in cancer immunotherapy 
Transducing T cells with CAR constructs as opposed to αβTCR constructs can have 
a number of advantages. CARs can function in a non-MHC restricted manner that is 
not dependent on antigen processing and presentation8, 12. In this way they can 
maintain their effectiveness against tumour cells that have downregulated MHC 
molecules, and theoretically all patients can be treated regardless of their HLA 
haplotype. Secondly, CARs recognize target molecules with far greater affinity than 
αβTCRs, and thus overcome T cell tolerance mechanisms that require high affinity 
ligation to permit T cell activation12. The drawbacks of using CARs include the fact 
they contain murine sequences in their ligand-binding domains, making these 
neoepitopes potential targets of the immune system. Additionally, although CARs are 
not MHC restricted, this does mean they are unable to recognize intracellular 
antigens. This means a smaller range of target antigens are available, and the cell 
surface targets could also be subject to downregulation as part of the tumour immune 
evasion process12. However, it is thought the benefits of using CARs outweigh the 
limitations; hence the large number of ongoing clinical trials involving CARs to target 
cancers. 
1.4.3 - The role of costimulatory molecules in T cell activation 
The costimulatory molecule CD28 is required for full T cell activation. CD28 on the T 
cell surface binds to CD80 or CD86 which are both expressed by antigen presenting 
cells (APCs). This provides a second signal alongside the MHC-peptide-TCR 
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interaction. CD28 ligation prevents the T cell undergoing anergy; and enhances the T 
cell response, cytokine production, proliferation and survival21. It is worth noting that 
although CD28 signalling is vital in naïve T cell activation, it is thought to be less 
important in effector and memory T cell responses17. 
Similarly, 4-1BB is expressed on T cells and interacts with its ligand 4-1BB ligand (4-
1BBL) that is expressed by activated APCs22. This interaction also constitutes an 
important costimulatory pathway for T cells, acting to increase T cell expansion, 
cytokine production and cytotoxic effector functions 23. Studies have demonstrated 
that 4-1BB-mediated costimulation can be both CD28-dependent and -independent22, 
24. Independently of CD28 signalling, 4-1BB ligation can prevent activation-induced 
cell death (AICD)25, but also 4-1BB can act synergistically with CD28 to lower the 
threshold for CD28 ligation needed to sustain proliferation and IL-2 production in 
mice22, 26, 27. In CD4+ T cells, 4-1BB signalling also regulates CD28 costimulation to 
skew towards IFN-γ producing TH1 cells that have shown to be important in anti-
cancer responses26. However, cytotoxic CD8+ T cells are preferentially expanded by 
4-1BB signalling when compared to CD4+ T cells28. Additionally, early studies 
suggest a role for 4-1BB in memory T cell induction and maintenance29, 30. This is 
interesting as memory T cells have been suggested to be better candidates than 
effector T cells for adoptive transfer as they survive longer in vivo13. Finally, it has 
been shown that agonistic anti-4-1BB antibodies can completely eradicate tumours in 
mice31, 32. 
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1.4.4 - Second generation CARs – comparing CD28 and 4-1BB costimulatory 
endodomains 
 
The use of second generation CARs has shown great potential as a feasible and 
effective cancer treatment. As mentioned, second generation CARs show much 
improved responses when compared to first generation CARs. Mouse studies 
revealed CD28-CAR+ T cells showed strong proliferative responses and produced 
high levels of effector cytokines in vivo17, 33, 34. In clinical trials there have also been 
successes. Savoldo et al. demonstrated CD28-CAR+ T cells expand and persist 
better than 1st generation CAR+ T cells of the same specificity in B cell non-Hodgkins 
lymphoma patients, despite seeing no clinical responses 15, 34. However, 
Kochenderfer et al. observed clinical remission in 75% of treated patients with 
advanced B cell malignancies after transfer of CD28-CAR+ T cells35, and in a 
separate trial, an even better complete response rate of 88% was reported36. Various 
other promising clinical trials with CD28-CARs are ongoing in patients with B cell 
malignancies (reviewed in REFS 13, 34). 
Finney et al. were the first to engineer secondary CARs to express 4-1BB 
endodomains. Their study revealed human T cells transduced with 4-1BB-containing 
CARs showed enhanced survival, proliferation and cytokine production compared to 
T cells transduced with 1st generation CARs. However, the production of IL-2, IFN-γ, 
TNF-α and granulocyte-macrophage colony-stimulating factor (GM-CSF) by 4-1BB-
CAR+ T cells was significantly lower than CD28-containing CAR-T cells, and there 
was no difference in antigen specific cell lysis when comparing cells transduced with 
4-1BB containing constructs to those transduced with 1st generation CARs in this 
particular study17. Notwithstanding, although another study suggested CD28-CAR+ T 
cells show slightly more proliferation, they also showed less IFN-γ and GM-CSF 
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production compared to 4-1BB-CAR+ T cells 37. Additionally, a comparison of 4-1BB 
and CD28-containing constructs in a mouse model of acute lymphoblastic leukaemia 
indicated the former endowed T cells with more favourable responses. 4-1BB-CAR+ 
T cells had a greater antileukemic efficacy and longer in vivo persistence than their 
CD28-containing counterparts38. Furthermore, T cells containing the 4-1BB construct 
were able to proliferate independently of CAR engagement. This has never been 
observed in CD28-containing CARs34, 38. It has also been reported that the 
incorporation of 4-1BB into the CAR construct increases multifunctional cytokine 
production of T cells in vivo 16, but other studies dispute this33. 
The 4-1BB construct has also been shown to have therapeutic applicability. Porter et 
al. conducted an autologous adoptive transfer with T cells engineered to express 4-
1BB into a chronic lymphocytic leukaemia (CLL) patient. This led to complete 
remission at the time of their publication39. A Follow up study by the same laboratory 
with a larger study group reported potent anti-tumour activity, long term persistence 
and ‘unprecedented and massive in vivo expansion’ of transferred 4-1BB-CAR+ T 
cells in CLL patients40. A third study by this group also reported highly potent 
responses in CLL patients when engineered 4-1BB-CAR+ cells were transferred, 
supported by B cell aplasia, decreased plasma cells and hypogammaglobulinemia. 
The cells expanded over 1000-fold post transfer, and some transferred cells even 
persisted as memory CAR+ T cells. Two of three patients in the study achieved 
complete remission41. Despite these encouraging findings, exhaustive comparison of 
4-1BB- containing CARs with CD28-containing CARs in human T cells has not yet 
been done (although a comparative clinical trial is currently in progress 
[clinicaltrails.gov NCT01044069] 19, 42. 
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1.5 - Study aims 
Many of these clinical trials use CARs that recognise CD20 – an antigen expressed 
only on B cells, and thus useful in treating B cell malignancies. However, solid 
tumours have proved more challenging targets for adoptive transfer therapy. This is 
due to a lack of tumour specific antigens, as well as due to the propensity of tumour 
cells to mutate to allow immune evasion – for example through decreasing antigen 
expression through MHC on the cell surface. Therefore, an alternative targeting 
mechanism is needed. One such alternative is through targeting the tumour 
vasculature. A recent study has reported that expression of the C-type lectin 
CLEC14a is greatly increased on tumour vasculature compared to healthy blood 
vessels43. This molecule is therefore potentially an excellent tumour target. 
Our lab uses 5 CAR constructs (CRT1-5) that are engineered to recognise CLEC14a. 
Our previous data with human T cells transduced with second generation CD28-
containing CARs show greatly enhanced IFN-γ responses, proliferation and cytotoxic 
activity when compared to both mock controls and first generation CARs with the 
same specificity. Furthermore, those cells transduced with CD28-CARs also persist 
for a prolonged period in mice, and significantly slow tumour growth in the Lewis lung 
carcinoma model [Steve Lee – personal communication]. The lab has recently 
engineered a new second generation construct with the 4-1BB costimulatory domain 
in place of the CD28 domain. Thus, given the discrepancies in the literature, this 
study aimed to see whether the CD28-CAR or the 4-1BB-CAR provided T cells with 
better proliferation and greater effector functions in vitro. T cells were transduced to 
express one of the CARs containing either CD28 or 4-1BB, and their transduction 
efficiencies, proliferation, cytokine production and cytotoxicity were compared. 
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2. MATERIALS AND METHODS 
2.1 – List of reagents and media 
Reagent/Media Components 
PBS 
1 PBS tablet [Oxoid, Basingstoke, UK] 
dissolved to total volume of 100mls with 
distilled water 
PBS/BSA 
PBS containing 2% (w/v) Bovine Serum 
Albumin (BSA)[Sigma] 
Complete RPMI 
RPMI (Roswell Park Memorial Institute) 1640 
[Sigma-Aldrich, Gillingham, UK], 1% L-
Glutamine (2mM)[Gibco], 100U/ml penicillin 
[Sigma], 100U/ml streptomycin [Sigma], 10% 
Fetal bovine serum (FBS) [Biosera, Ringmer, 
UK] 
T cell media (TCM) 
Complete RPMI containing 1% Human 
Serum [Biosera, Ringmer, UK] 
Transfection media 
DMEM (Dulbecco’s Modified Eagle 
Medium)[Sigma], 1% L-glutamine 
(2mM)[Gibco], 10% Fetal bovine serum 
(FBS) [Biosera, Ringmer, UK]  
Complete DMEM 
Transfection media containing 100U/ml 
penicillin [Sigma], 100U/ml streptomycin 
[Sigma] 
MACS buffer 
PBS, 2mM ethylenediaminetetraacetic acid 
(EDTA)[Sigma], 0.5% BSA [Sigma] 
Coating buffer 
0.1M Na2HPO4 - adjusted to pH9 with 
addition of 0.1M NaH2PO4 
Blocking buffer 
PBS containing 1% (w/v) BSA [Sigma], and 
0.05% (v/v) Tween-20 [Sigma], sterile filtered  
with 0.45μm filter 
 
Table 2.1 - List of cell culture media and other reagents used in this investigation 
 
2.2 – T cell transfection and transduction 
Phoenix A cell culture: 
Phoenix A cells [Nolan lab, Stanford University] were thawed and cultured at 37OC, 
5%CO2 in complete DMEM until 50-80% confluent. Media was removed and cells 
washed once with PBS before 1X Trypsin-EDTA [Gibco, UK] was added for 
approximately 2 minutes to bring cells to a single cell suspension. Complete DMEM 
was added and cells centrifuged (355g, 5 minutes). Cells were then resuspended in 
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transfection media, counted with a haemocytometer, and seeded into seven T25 
flasks [Corning, NY, USA] – 2 x 106 cells in a volume of 10mls per flask. These flasks 
were cultured overnight (37OC, 5%CO2). 
Transfection: 
7 sterile 1.5μl microcentrifuge tubes were prepared – 4 for each of the vectors used 
and 3 for mock tranfection controls. The second generation CAR-containing plasmids 
used were as follows: CRT3 CD28 and CRT5 CD28 [both generated by Zhuang, X.]; 
and CRT3 4-1BB and CRT5 4-1BB [both generated by Clarke, L]. 600μl Optimem 
[Gibco, UK] was added to each tube, alongside 3μg relevant plasmid DNA. 3μl of 
retroviral vector pCL ampho (1μg/ml) [Imgenex, San Diego, USA] was added to the 
mixtures containing plasmids to maximise recombinant retrovirus titres. 24μl PEI 
stock (1mg/ml) [Sigma-Aldrich, Gillingham, UK] was then added to all tubes. These 
mixtures were vortexed and incubated at room temperature for 10 minutes. 
Meanwhile, Phoenix A cell culture media was removed and 3.5ml fresh transfection 
media added. After 10 minutes, the plasmid mixtures were added to the relevant 
Phoenix A cells, mixed well and placed into incubation (37OC, 5% CO2). 24 hours 
later, media was removed and fresh transfection media added before cells were 
placed back in the incubator for a further 24 hours. 
Transduction: 
Peripheral blood mononucleocytes (PBMCs) were counted with a haemocytometer 
and resuspended at 1 X 106 cells/ml in TCM. Cells were stimulated with 30ng OKT3 
[eBioscience, San Diego, USA], 30ng anti-CD28 [R&D systems, Oxfordshire, UK], 
and 100U/ml IL-2 [Novartis, UK]; placed into T100 flasks and incubated overnight 
(37OC, 5% CO2). 
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For the transduction procedure, 6 well non-tissue culture treated plates were coated 
with 2mls/well retronectin (30μg/ml) [Clontech, Saint-Germain-en-Laye, France] for 3 
hours. After removal of the retronectin, wells were blocked with 2.5mls sterile 
PBS/BSA for 30 minutes, and then washed three times with PBS. Phoenix A cell 
culture supernatants were harvested and centrifuged (400g, 5 minutes) to pellet any 
residual phoenix A cells. Supernatants were transferred to the retronectin-coated 
wells and centrifuged (2000g, 120 minutes, 32OC) to allow spinfection. Meanwhile, 
the stimulated T cells were counted again, centrifuged (355g, 5 minutes) and 
resuspended in TCM containing 100U/ml IL-2 to a concentration of 1 x 106 cells/ml. 
These cells were placed in the incubator for 15 minutes to recover. After spinfection, 
retronectin-coated plates were washed once with PBS, and 5 x 106 PBMCs added to 
each well. Plates were spun once more (355g, 5 minutes) and incubated overnight. 
The following day, cells were transferred to tissue culture treated 6 well plates and a 
further 3 mls TCM (containing 100U/ml IL-2) was added to each well.  
2.3 – Cell culture 
Transduced T cell cultures were examined regularly, and fresh TCM(+ 100U/ml IL-2) 
added, or cells split when necessary. Some cells were cultured on CLEC14A-coated 
plates: non-tissue culture treated plates were incubated with 2mls of human 
CLEC14a-Fc [produced by by Zhuang, X.] (1μg/ml – dissolved in PBS) for 3 hours at 
37OC, 5% CO2, washed once with PBS, and T cells added. Cells were cultured in 
CLEC-14a-coated plates for up to a week, after which time they were transferred to 
6-well tissue culture treated plates. 
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2.4 – Flow cytometry 
Surface Staining: 
For single colour staining, 200μl of cells were transferred to FACS tubes, 2mls of 
MACS buffer added and the cells centrifuged for 3 minutes, 411g. Supernatant was 
removed and cells were resuspended with relevant fluorescently labelled antibodies 
for 30 mins in the dark at 4OC. Cells were washed with MACS buffer as before (2mls 
MACS added and centrifuged 3 minutes, 411g) and resuspended in 200μl MACS 
buffer ready for flow cytometric analysis. Similarly, for multicolour staining, cells were 
transferred to 96 well V-bottom plates, washed in MACS buffer, incubated with 
relevant antibodies for 30 mins on ice, washed once more, and then transferred to 
FACS tubes for analysis. If fixing was required, cells were resuspended in 1% 
Paraformaldehyde in MACS buffer. Compensation beads were prepared by the 
addition of one drop of positive and one drop of negative compensation beads into 
100μl of MACS buffer, addition of the relevant antibody, incubation at 4OC for 30 
minutes, addition of a further 2 mls MACS buffer and then centrifugation (302g, 10 
minutes). Analysis was carried out on either a BD biosciences Accuri C6 flow 
cytometer, using Accuri CFlow Plus v.1.0.227.4 software, or a BD Biosciences LSR II 
flow cytometer, using BD FACSDiva v.8.0 software. Data were analysed offline using 
FlowJo v.7.6.5 software and BD FACSDiva v.8.0 software, and data presented using 
Graphpad Prism v.5 software. 
 
CFSE assay: 
 
Maxisorp 96-well plates (Nunc) were coated with human CLEC14a-Fc (1μg/ml in 
PBS), or human Fc fragment [Bethyl, Montgomery, USA] (1μg/ml in PBS) and 
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incubated at 37OC for 5 hours. T cells were counted with a haemocytometer and the 
required volumes aliquoted into falcon tubes before each transduced T cell line was 
diluted with mock transfected cells in order to equalize the percentages of transduced 
cells for all samples. Cells were centrifuged (411g, 5 minutes) and resuspended at a 
concentration of 1 x 106 cells/ml in a 1μM solution of CFSE (carboxyl fluorescent 
succinimidyl ester) [Invitrogen, UK] in PBS. Samples were initially incubated for 15 
minutes (37OC, 5% CO2), before they were centrifuged (411g, 5 minutes) and 
resuspended in TCM at 1 x 106 cells/ml and incubated at 37OC, 5% CO2 for a further 
30 minutes. Cells were washed twice (first in RPMI, then TCM – both times at 411g, 
3 minutes) and resuspended in TCM + IL-2 (10U/ml). 
 
After the 5-hour coating step, Maxisorp plates were washed with TCM, and then 3 x 
105 cells added to the wells. T cells cultured with 600U/ml IL-2 were included as 
positive controls. Plates were incubated for 4-6 days. Cells were then transferred to 
FACS tubes and washed once in MACS buffer (411g, 3 mins). A 1/100 dilution of 
vital dye [Life Technologies, UK] was added to each tube, and tubes incubated in the 
dark at room temperature for 20 minutes. Following this, surface staining and flow 
cytometric analysis was carried out as above. 
 
Degranulation assay: 
 
Human umbilical vein endothelial cells (HUVECs) [courtesy of Cawkwell L.] were 
washed gently with PBS before 1X Trypsin-EDTA was added to dissociate cells. One 
wash was carried out with TCM (centrifuged at 355g, 5 minutes), then HUVECs were 
resuspended in TCM and counted with a haemocytometer. 10,000 HUVECs per well 
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were added to a 96-well flat bottom plate. T cells were also counted with a 
haemocytometer and 5 x 104 cells added to the HUVECs. Well volumes were made 
up to 200μl with TCM. Equivalent wells of T cells alone were also set up. First 5μl 
anti-CD107a-FITC antibody and then 5μl of monensin (0.25mM in TCM)[Sigma 
Aldrich, Gillingham, UK] were added to each well and mixed thoroughly. Plates were 
centrifuged for 3 mins, 210g and incubated for 12 hours (37OC, 5% CO2). Additional 
surface staining and analysis was carried out as above. 
 
Apoptosis assay: 
 
Cells placed into hypoxia were cultured in a 96 well plate at a density of 1.5 x 106 
cells/ml, before being placed into a hypoxia chamber set to 1% O2, 37
OC for 2 days. 
Equivalent controls were cultured at the same density under normoxia (37OC, 5% 
CO2). Surface staining was carried out using the FITC Annexin V apoptosis detection 
kit II [BD Biosciences, San Jose, USA]. Cells were washed twice with MACS buffer 
and resuspended in 1X Binding buffer at a concentration of 1 x 106 cells/ml.100μl of 
cell suspensions were transferred to FACS tubes and 5μl of each the Annexin V and 
propidium iodide (PI) antibodies were added. For compensations, some cells were 
stained with Annexin V only, or PI only. Cells were incubated for 15 mins in the dark, 
and 400μl binding buffer added to each tube. Cells were analysed by flow cytometry 
using the BD Biosciences LSR II flow cytometer and analysed with BD FACSDiva 
v.8.0 software. Data was presented using Graphpad Prism v.5 software. 
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2.5 – IFN-γ sandwich enzyme-linked immunosorbent assay (ELISA) 
Maxisorp 96-well plates (Nunc) were coated with human CLEC14a-Fc (1μg/ml in 
PBS), mouse CLEC14a-Fc [Produced by Noy, P.] (1μg/ml in PBS) or human Fc 
fragment (1μg/ml in PBS) for 3 hours at 37OC. Plates were washed once with PBS 
and T cells at correct concentrations added. T cells were prepared as follows. Each T 
cell line was counted and aliquots diluted with mock to balance the percentages of 
transduced cells (as previously in CFSE assay). T cells were washed with RPMI 
(spun 411g, 5 mins) and resuspended at the required concentration in TCM before 
being transferred to the Maxisorp plates. The plate was centrifuged (411g, 3 mins) 
and incubated for 16-24 hours at 37OC, 5% CO2. On the same day, a new Maxisorp 
96-well plate was coated with anti-human γIFN antibody (0.75μg/ml) [Thermo 
Scientific, MA, USA] diluted in coating buffer, sealed with Nescofilm and placed at 
4OC overnight. 
The following day, primary antibody was flicked off and blotted, before the plate was 
blocked with blocking buffer for 2 hours (200μl/well) at room temperature. Plates 
were washed 4 times with PBS containing 0.05% (v/v) Tween-20 (PBS/Tween), then 
50μl of T cells or recombinant human IFN-γ standards [Sigma-Aldrich, Gillingham, 
UK] added to relevant wells. IFN-γ standard concentrations used were 20000, 10000, 
5000, 2500, 1250, 625, 312.5 and 0 pg/ml. Plates were incubated at room 
temperature for 3 hours, after which 4 more washes with PBS/Tween were carried 
out and 50μl of biotinylated anti-IFN-γ antibody (0.75μg/ml) [Thermo Scientific, MA, 
USA] was added to each well. After an hour at room temperature, plates were 
washed 4 times with PBS/Tween, and Extra-avidin peroxidase [Sigma] diluted 1/1000 
in blocking buffer was added – 50μl per well. After a 30 minute incubation period at 
room temperature, plates were washed 8 times with PBS/Tween and 50μl of TMB 
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substrate [Invitrogen, UK] was added to each well. Approximately 20 minutes later, 
when the colour had developed, the reaction was stopped with 1M Phosphoric acid 
(50μl/well). Absorbance at 450nm was measured on a Bio-Rad 680 plate reader 
using Bio-Rad Microplate manager v.5.2.1 software. The IFN-γ concentrations were 
determined from the standard curve (calculations performed with Microsoft Excel 
2007 software) and these were subtracted from the responses against Fc alone. 
Data were presented using Graphpad Prism v.5 software. 
2.6 – Antibody list 
Specificity Conjugation 
Species/ 
Isotype 
Final 
Dilution 
Experiment Company 
Human CD34 PE-Cy5 
Mouse 
IgG1 
1/50 
Flow 
cytometry 
BD 
Pharmingen 
Human CD4 PE-TR 
Mouse 
IgG1 
1/100 
Flow 
cytometry 
Beckman 
Coulter 
Human CD8 eFluor450 
Mouse 
IgG1 
1/50 
Flow 
cytometry 
eBioscience 
Human CD8 PE-TR 
Mouse 
IgG1 
1/50 
Flow 
cytometry 
Beckman 
Coulter 
Human 
CD107a 
FITC 
Mouse 
IgG1 
1/20 
Flow 
cytometry 
BD 
Pharmingen 
Human 
Annexin V 
FITC - 1/20 
Flow 
cytometry 
BD 
Biosciences 
Human IFN-γ - 
Mouse 
IgG1 
1/1360 ELISA 
Thermo 
Scientific 
Human IFN-γ Biotin 
Mouse 
IgG1 
1/1333 ELISA 
Thermo 
Scientific 
 
Table 2.2 - List of antibodies used in this study.  PE - Phycoerythrin, Cy5 – Cyanine 5, 
TR – Texas Red, FITC - Fluorescein isothiocyanate. 
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3. RESULTS 
3.1 – CD28 CARs show slightly better T cell transduction efficiencies, and show 
greatly enhanced CLEC14A-mediated expansion in culture compared to their 4-
1BB containing counterparts 
 
T cell expression of the CARs was enabled by retroviral transduction mediated by 
Phoenix A cells. On day 4 post transduction, T cells were assayed to determine the 
efficiency of transduction of the CAR in the T cell population. This was achieved 
through flow cytometric detection with a fluorescently-labelled anti-CD34 antibody, as 
each CAR vector contains a truncated CD34 molecule. As CD34 is not present on T 
cells naturally, this method allows for specific detection of transduced T cells. 
Across 4 separate transduction procedures transduction efficiency was fairly 
consistent and generally between 10 and 20% of lymphocytes (Fig. 3.1B). The 
exception is the third transduction, which resulted in far lower efficiencies (ranging 
between 1.55 – 2%). The reasons for this are unclear, but may be due to 
overconfluency of Phoenix A cells during the transfection procedure. 
Upon comparing CD28-containing constructs with 4-1BB-containing constructs, the 
mean percentages of transduced cells were slightly lower in the latter. Although the 
mean difference is slight, in two out of three of the repeats, the efficiency of 
transduction in T cells containing CD28-containing CARs (CAR-CD28+ T cells) was 
clearly higher than their 4-1BB counterparts (CAR-4-1BB+ T cells). Therefore, in 
conclusion, both 4-1BB and CD28-containing constructs are capable of transduction, 
but marginally higher efficiency is seen with CD28. 
Additionally, T cells were cultured on plates coated with human CLEC14A-Fc in 
attempt to selectively expand those cells that expressed the CLEC14A specific CAR.  
26 
 
Figure 3.1 – Efficiency of transduction of each CAR-construct. 
A – Gating strategy used. First lymphocytes were gated on according to their forward and 
side scatter parameters (FSC-A and SSC-A respectively). Next the area of forward scatter 
(FSC-A) and the height of forward scatter profiles (FSC-H) were plotted for the gated 
population to omit everything but single cells. Finally a histogram of PE-Cy5 (CD34) signal 
was plotted. The gate determining CD34+ cells was set according to the mock-transduced 
PE-Cy5 histogram profile (mock-transduced cells – upper, example CAR transduction – 
lower. B – Transduction efficiencies of 4 CARs in T cells. Graph shows the efficiency of 
the transduction procedure as the percentage of CD34+ cells of singlet lymphocytes. Each T 
cell line, and mock-transduced cells are plotted. Data points from all experiments are shown 
(n=4) and line represent mean values. 
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CAR-CD28+ T cells showed marked expansion after coating with CLEC14A, whereas 
the percentage of CAR-4-1BB+ T cells did not increase at all (Fig. 3.2). This pattern 
was consistent in other repeats. 
3.2 – Minimal antigen-specific proliferative responses observed to plate-bound 
CLEC14A 
 
Next, we wanted to see if there was any difference in proliferative responses to 
CLEC14A by CAR-4-1BB+ T cells when compared to CAR-CD28+ T cells. When cells 
were stained on day 4 after culture with CLEC14A-coated plates, (Fig.3.3B – top 
panel) CD8+ T cells transduced with CRT5-CD28 displayed the greatest proliferative 
response. For T cells expressing this construct, proliferation against CLEC14A was 
increased compared to proliferation against Fc only control plates, suggesting some 
proliferation was specific. For the other constructs, the percentage of divided cells 
following CLEC14A stimulation is not increased when compared to Fc controls, 
showing little antigen-specific proliferation has occurred. The same pattern could be 
seen in CD8- cells (assumed to be CD4+ T cells), with only T cells transduced with 
CRT5-CD28 showing any antigen-specific proliferation. When the CD8+ T cells were 
compared to CD8- cells overall, levels of proliferation were higher in the CD8+ 
population for cells cultured with CLEC14A and Fc controls, while the cells cultured 
with high levels of IL-2 showed similar proliferation in both subsets. 
When cells were stained on day 6 after culture (Fig. 3.3B – bottom panel), the overall 
proliferative responses were lower than those on day 4. The greatest proliferative 
response seen was in CD8+ T cells transduced with CRT3-CD28, but as the 
response to Fc alone was greater, this proliferation cannot be considered specific. 
The only specific proliferation seen was in T cells transduced with CRT3-CD28 in the  
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Figure 3.2 – Transduction efficiencies before and after culture on human CLEC14A-coated 
plates. 
This example shows the transduction efficiencies measured in T cells that had been cultured with 
human CLEC14A-Fc (right panel) or standard tissue culture plates (left panel). T cells were 
cultured on CLEC14-A coated plates for 6 days. Analysis of T cells cultured on non-coated plates 
was done on the same day to enable fair comparison. First row shows CD28 constructs second 
row shows 4-1BB constructs and bottom row shows mock controls. Percentages of CD34+ cells are 
given with each plot. 
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Figure 3.3 – Proliferative responses to plate-bound human CLEC14A. A – Gating 
strategy. 
First singlet lymphocytes were gated on as described as previously. Next, vital dyehi cells 
were excluded to remove dead cells from analysis. Quadrant gates were drawn on remaining 
cells such that the percentages of CD34+CD8+ and CD34+CD8- cells could be analysed for 
CFSE incorporation and plotted. The dialogue box illustrates gating hierarchy. B – 
Proliferation responses at days 4 and 6 post culture with human CLEC14A. Graphs 
show the percentage of singlet CD34+ lymphocytes that have undergone cell division in each 
T cell line. Top and bottom panels represent the response at days 4 and 6 post culture 
respectively (each day was the result of a separate experiment using separate donors).  Left 
panels show CD8+ cells, while right panels show CD8- cells. Key: blue bars=T cells cultured 
with human CLEC14A-Fc, white bars=T cells cultured with Fc only, red bars= T cells cultured 
with a high concentration of IL-2 (600U/ml). N=1. 
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CD8- fraction. Similarly to day 4, more cell division was observed in CD8+ T cells as a 
whole than in CD8- cells. Overall, these results show T cells transduced with either 
CD28 or 4-1BB constructs fail to produce a substantial antigen-specific proliferative 
response to plate bound CLEC14A. However, this could conceivably be due to the 
assay failing as far more specific proliferation was expected in these cells. 
3.3 – CD28 constructs endow T cells with superior IFN-γ production in 
response to CLEC14A than their 4-1BB-containing counterparts 
 
The effector cytokine IFN-γ is produced by CD4+ TH1 T cells and CD8
+ T cells and is 
important in the anti-tumour response44. To this end, we measured the IFN-γ 
production by the transduced T cells in response to different concentrations of plate-
bound CLEC14A using ELISA methodology. The responses of CAR-CD28+ T cells 
were compared to CAR-4-1BB+ T cells. Both T cells that had been cultured in tissue-
culture treated plates, and T cells that had been previously cultured in CLEC14A-
coated plates were used in these experiments. 
T cells expressing CRT3 and CRT5 CD28 constructs both display a strong IFN-γ 
response, far higher than their corresponding 4-1BB-CAR+ engineered T cells (Fig. 
3.4A). The first repeat resulted in CRT3 CD28+ T cells producing the most IFN-γ, 
whereas in the second experiment CRT5 CD28+ T cells produced higher IFN-γ 
levels. The responses of either of the 4-1BB-construct expressing cell populations 
were not significant, showing no increase from the production by mock-transduced 
cells. Therefore in both experiments where T cells that were previously cultured 
without CLEC14A, CD28 constructs perform consistently better than 4-1BB in 
inducing IFN-γ production in T cells. CRT5 CD28+ T cells and CRT3 CD28+ T cells 
may be able to produce similar levels of IFN-γ at high CLEC14A concentrations  
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Figure 3.4 – IFN-γ response of transduced T cells in response to plate-bound human 
CLEC14A. 
A – T cell IFN-γ production in response to a range of CLEC14A concentrations.  Graphs show 
the IFN-γ production (in pg/ml) of each T cell line in response to CLEC14A concentrations from 10-
0.33μg/ml as measured by sandwich ELISA.  Plotted results show the specific IFN-γ response 
(response against CLEC14A-Fc with response against Fc alone subtracted). Red lines represent 
CD28-CAR+ T cells, blue lines represent 4-1BB-CAR+ T cells and black lines represent mock-
transduced T cells. Error bars show standard deviations. Top panel shows the 1st experiment, while 
the bottom panel shows results from the 2nd experiment carried out (*=T cells have previously been 
cultured in human CLEC14A-Fc coated plates [right hand side]). B – Comparison of maximal IFN-γ 
responses in transduced T cells. Bar charts show the level of IFN-γ secretion in each T cell line at 
the highest CLEC14A-Fc concentration - 10μg/ml. As previously results displayed show the specific 
IFN-γ response with responses against Fc alone subtracted. Both repeats for each experiment are 
shown in grouped bars (black bars=previously cultured in CLEC14A-coated plates, white 
bars=cultured in standard tissue culture-treated plates). 
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(10μg/ml), but it appears that CRT5 CD28+ T cells are able to produce IFN-γ in 
response to lower concentrations of CLEC14A (3.3-1μg/ml). 
T cells that had been previously cultured on human CLEC14A-coated plates were 
also analysed for IFN-γ production (Fig. 3.4A). In the first ELISA, no responses were 
seen in any of the cells. The reasons for this are unknown, but the expected 
response was seen for the IFN-γ standards in this experiment. In the second ELISA, 
once again CD28-CAR + T cells produced more IFN-γ than the 4-1BB-CAR+ T cells. 
Furthermore, CRT5 CD28+ T cells produced higher levels of IFN-γ at every 
concentration of CLEC14A tested when compared to CRT3 CD28+ T cells. Neither 
CRT3 4-1BB+ T cells, or CRT5 4-1BB+ T cells showed any IFN-γ response above 
background (mock-transduced T cell) levels. As expected, the highest magnitude of 
response was seen in cells that had previously been cultured in CLEC14A-coated 
plates (in CRT5-CD28+ T cells) due to antigen specific cell expansion. Finally, the 
different T cell lines were also tested against mouse CLEC14A (Fig. 3.5). 
Surprisingly, no IFN-γ response was seen in any of the T cells studied, despite 
previous data from the lab and others indicating CAR-CD28+ T cells produce IFN-γ in 
response to mouse CLEC14A [Steve Lee – personal communication]. This is most 
likely due to the batch of mouse CLEC14A, as no other experiments in the lab with 
this batch led to any IFN-γ production, whereas robust responses had been seen in 
experiments with previous batches [Steve Lee – personal communication]. 
These data are summed up in Fig. 3.4B. The maximal IFN-γ responses against 
human CLEC14A of the CD28-CAR+ T cells are far greater than those of the 4-1BB-
CAR+ T cells, which themselves are no greater than the IFN-γ responses of mock-
transduced T cells. No response against mouse CLEC14A was seen in these 
experiments. 
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Figure 3.5 - IFN-γ response of transduced T cells in response to plate-bound mouse 
CLEC14A. 
Graphs show IFN-γ production by T cells of each line against mouse CLEC14A-Fc 
concentrations of 10-0.33μg/ml. For key see figure 4A legend. Red lines represent CD28-CAR+ 
T cells, blue lines represent 4-1BB-CAR+ T cells and black lines represent mock-transduced T 
cells. Right panel (marked*) indicates T cells have previously been cultured on mouse 
CLEC14A-Fc coated plates. 
 
34 
3.4 – Enhanced cytotoxicity of T cells engineered to express CD28-CARs, 
compared to cells that express 4-1BB-CARs 
 
Building on the previous IFN-γ response results, we next sought to investigate if 
there was any difference in antigen-specific cytotoxicity in T cells transduced with the 
CD28 or 4-1BB constructs. CD107a (also called lysosomal-associated membrane 
protein-1 [LAMP-1]) has been shown to be a reliable marker of induced T cell 
degranulation45. Therefore, we cultured T cells from each line with or without HUVEC 
cells (that naturally express CLEC14A43) and stained them for CD107a to monitor 
their cytotoxic activity. 
Cells cultured in just media alone resulted in low percentages of CD107a staining, 
with a maximum level of 5.6% being observed (Fig. 3.6B). In the presence of 
HUVECs, CD28-CAR+ T cells display a far superior degranulation response 
compared to T cells expressing 4-1BB-CARs. 4-1BB-CAR+ T cells show negligible or 
no degranulation response above that of mock-transduced T cells. 4-1BB-CAR+ T 
cell cytotoxicity is also not significantly increased in the presence of HUVECs. Taken 
together, these data show T cells expressing CD28-CARs are far superior at 
mediating an antigen-specific cytotoxic response when compared to 4-1BB-CARs. 
3.5 – 4-1BB-CAR+ T cells are more resistant to apoptosis than CD28-CAR+ T 
cells, especially under hypoxic culture conditions 
 
In vivo, many solid tumours develop a state of relative hypoxia compared to healthy 
tissue46. Therefore, for adoptive T cell therapies to be effective, the transferred T 
cells must be able to survive in hypoxic conditions. Some reports claim that T cells 
expressing CARs with 4-1BB costimulatory endodomains are more resistant to 
apoptosis than T cells expressing CARs with CD28 costimulatory endodomains [Carl  
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Figure 3.6 – Degranulation response of transduced T cell lines to natural CLEC14A-
expressing HUVECs. 
A – Gating strategy. First lymphocytes were gated on (P1), then singlet cells (P2). The 
CD34+ fraction was determined and of these the percentage of CD107a+ cells was 
calculated. Box illustrates gating hierarchy. B – Degranulation response of the 4 
different transduced T cell lines. Bar chart shows response of the 4 lines and mock-
transduced cells (n=1).  Bar heights represent the percentage of CD34+ singlet lymphocytes 
which are CD107a+ (for mock-transduced cells bar heights represent the percentage of 
total singlet lymphocytes that are CD107a+). Black and white bars signify T cells have been 
cultured with and without HUVECs respectively. These experiments used T cells that were 
previously cultured with human CLEC-14A-Fc. 
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June – personal communication]. To test this, cells were stained for the apoptosis 
marker Annexin V after culture in hypoxia or normoxia. 
The first observation made was that as expected all cell lines (with the exception of 
mock-transduced controls) showed higher percentages of apoptosis at 1% O2 than at 
normoxia (Fig. 3.7B). At normoxia, 4-1BB-CAR+ T cells show marked resistance to 
apoptosis compared to mock-transduced T cells, and even more so compared to 
CD28-CAR+ T cells. Similarly, under hypoxia the percentages of apoptotic cells were 
much lower in the 4-1BB-CAR+ T cell lines than in the CD28-CAR+ T cell line. 
Overall, CRT5+ T cells appear better at resisting apoptosis than CRT3+ T cells, with 
the CRT5-4-1BB construct performing best of all. Together these results agree with 
previous data, suggesting CARs with 4-1BB costimulatory endodomains allow for 
better T cell survival in both normoxia and hypoxia when compared to CARs with 
CD28 costimulatory endodomains. 
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Figure 3.7 – Apoptosis in response to normoxia and hypoxia. 
A – Gating strategy.  Cells gated on lymphocytes first (P1), followed by single cells 
(P2) and finally Annexin V+ apoptotic cells (P3). Box illustrates gating hierarchy. B – 
Percentages of apoptotic cells in response to hypoxic/normoxic conditions. Chart 
shows the percentage of lymphocytes that are apoptotic (Annexin V+) in response to 
hypoxia (1% O2 - black bars) or normoxia (21% O2 - white bars)(n=1). These 
experiments used T cells that were previously cultured with human CLEC-14A-Fc. 
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4. DISCUSSION 
2nd Generation CARs have shown promising early successes in phase 1 clinical trials 
in leukaemia. However, targeting solid tumours has proved to be a bigger challenge. 
Our lab uses a new approach; targeting tumour vasculature specifically through the 
C-type lectin CLEC14A. Building on successes using CARs containing CD28 
costimulatory endodomains, this investigation aimed to compare this CAR to a new 
CAR containing a 4-1BB costimulatory endodomain. 
Transduction efficiencies across the T cell lines were generally in the range of 10-
20%. This is in line with what others in the lab achieve [Steve Lee – personal 
communication]. The mean percentages of CD28-CAR+ T cells were slightly higher 
than those of the 4-1BB-CAR+ T cells, but the results show that both CD28 and 4-
1BB containing constructs can clearly be transduced into T cells. This bodes well for 
future experiments using 4-1BB-CAR constructs and indicates transfection and 
transduction methodology need not be altered. However, 4-1BB-CAR+ T cells do not 
appear able to expand in response to plate-bound antigen in the same way as CD28-
CAR+ T cells can (based on three repeats – one representative example shown in 
figure 3.2). This could reflect possible differences in the abilities of 4-1BB and CD28 
to activate T cells in response to antigen, but as human T cells are mostly memory 
cells, it would be expected 4-1BB would be better at inducing activation in response 
to antigen than CD2829, 30.Needless to say this issue remains unresolved and needs 
further study.  
Given the lack of clonal expansion seen by 4-1BB-CAR+ T cells against CLEC14A, 
an associated trend would have also been expected in the proliferation assay 
experiment. However, little antigen-specific proliferation was seen in any of the 4 
constructs. This is in disagreement with previous data that T cells with either 
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construct type can proliferate in response to antigen, with the response of CD28-
CAR+ T cells being stronger17. It is possible this discrepancy may be due to a degree 
of exhaustion or anergy due to overexposure to antigen or to the T cell mitogen IL-2 
in our experiments. It is also possible the assay did not work if the T cells were in a 
poor condition which prevented any substantial proliferation in vitro. However, taking 
this data at face value, more generalised proliferation was seen in the cells 
expressing CD28-CARs. This fits with the fact that 4-1BB-CAR+ T cells failed to 
expand to CLEC14A in plates previously, but is perhaps somewhat surprising given 
that 4-1BB signalling is thought to preferentially expand CD8+ T cells27. CD8+ T cells 
seemed to proliferate more than CD8- cells, but this was true for CD28-CAR+ T cells 
as well as 4-1BB-CAR+ T cells. More repeats of this assay need to be carried out 
(currently n=1) in order to understand these findings. Together the results suggest 
CD28-CARs transduce slightly better, and allow for more general proliferation of T 
cells when compared to 4-1BB-CARs. 
Next the transduced T cells were analysed for the production of IFN-γ. When 
compared to 4-1BB-CAR+ T cells, CD28-CAR+ cells showed a far superior IFN-γ 
response to human CLEC14A. Against mouse CLEC14A, no response above 
background was seen in any T cell line. This may be due to the batch of mouse 
CLEC14A used, as others in the lab had been experiencing anomalous results with 
this batch. Future experiments with a new batch of mouse CLEC14A should produce 
an IFN-γ response from T cells, as others in the lab have shown previously with older 
batches [Steve Lee – personal communication]. Nonetheless, in the response 
against human CLEC14A, it is clear that CD28-constructs are favourable in inducing 
production of the inflammatory cytokine IFN-γ in T cells. 
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Concordantly, CD28-CAR+ T cells also performed favourably in another test of T cell 
effector function – cytotoxicity. In the presence of CLEC14A expressing HUVECs, the 
degranulation response of T cells expressing the CD28-CARs were far greater than 
the minimal T degranulation response of T cells expressing 4-1BB-CARs. Although 
this is only from 1 repeat, the differences seen are substantial. 
We also wanted to investigate levels of apoptosis in transduced T cells, including 
under hypoxic conditions, as in vivo many solid tumours exist in a state of hypoxia46. 
4-1BB-CAR+ T cells displayed reduced apoptosis in response to both normoxia and 
hypoxia compared to their CD28-CAR+ T cell counterparts. This supports data from 
Carl June’s lab at the University of Pennsylvania which suggested 4-1BB constructs 
mediate resistance to apoptosis to a greater degree than CD28 constructs [Carl June 
– personal communication]. As the level of mock-transduced cells lay intermediate to 
4-1BB-CAR+ T cells and CD28-CAR+ T cells, it can also be inferred that CD28 
constructs make T cells more susceptible to apoptosis, though the experiment needs 
repeating to be sure of this. This would make sense as CD28-CAR+ T cells were 
shown to produce more IFN-γ and displayed a greater cytotoxic response, meaning 
these cells were more active than their 4-1BB-CAR+ counterparts. Consequently, 
they could be subject to increased T cell exhaustion and apoptosis. Future studies 
looking at anergy and exhaustion markers such as programmed cell death-1 (PD-1), 
T-cell immunoglobulin domain and mucin domain 3 (TIM3) or lymphocyte-activation 
gene 3 (LAG-3) in the transduced T cells will help understand this further. 
Taking the results together, it appears CD28-CAR+ T cells transduce slightly better; 
and show enhanced in vitro IFN-γ and cytotoxic responses to antigen than 4-1BB-
CARs. These data fit with previous reports that show IFN-γ production in CD28-CAR+ 
T cells is higher17, but disagree with others that claim 4-1BB+ T cells produce more 
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IFN-γ37. Reasons for these differences could be due to different transduction 
methods (for example electroporation vs viral transduction), different assay methods 
and different antigen targets. Also, some data suggests 4-1BB constructs are better 
than CD28 constructs in clinical trials39-41. Differences observed in our study to these 
could include low repeat number, overstimulation of T cells in culture or the general 
shortcomings of in vitro cell culture models. 
 4-1BB constructs did allow for better survival, but this may also be due to lack of 
activation induced cell death and exhaustion as they are less active than cells 
transduced with CD28-CARs. As mentioned, it is possible T cell overactivation 
(resulting in anergy, exhaustion or apoptosis) could have played a big role in the 
outcome seen. Long term exposure to the T cell mitogen IL-2 and overstimulation 
with antigen could have resulted in this. Moreover, cells were kept in culture for up to 
three weeks. Towards the end of this period, cells may be less functionally active and 
comparisons became more difficult. Future experiments should therefore aim to 
culture cells for the minimum period possible. Nonetheless, CD28-CAR+ T cells only 
showed a maximum of 25% apoptosis under hypoxia, indicating the majority still 
survive. Combined with the increased effector functions of these cells, these data 
alone would indicate CD28-CARs are the better option for further study into adoptive 
T cell transfer therapy for solid tumours, although more repeats of these data are 
clearly needed to back up these conclusions. An alternative option is to use 3rd 
generation CARs with both CD28 and 4-1BB costimulatory endodomains 
incorporated. Studies into such constructs are at an early stage, but are very 
promising; some suggesting enhanced proliferation, survival, cytokine production and 
tumour eradication in vivo13, 37, 47. 
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Following on from this work, the two constructs could be compared in vitro in the 
following ways. Cytokine profiles could be studied by flow cytometry, and the 
production of these assayed in each cell line by ELISA methodology. These 
cytokines could include tumour necrosis factor-α, IL-2 and GM-CSF, similar to 
previous reports 17. T cell subsets from each line could be analysed by flow 
cytometry. This could allow us to see if either construct resulted in a skewing towards 
specific T-helper subsets; or central or effector memory cells. Additionally, cloning 
work could be done to incorporate luciferase into these CARs. This would allow T 
cells expressing these constructs to be injected into cancerous mice and their 
migration patterns visualised by whole body intravital imaging. This way both CD28-
CAR+ T cells and 4-1BB-CAR+ T cells could be compared directly for site specific cell 
migration and tumour size over time. Further work should be done to determine if 
CD28 constructs are also superior to 4-1BB constructs in terms of effector functions 
in vivo. Overall, based on these results CD28-CARs look a better option than 4-1BB 
CARs for adoptive immunotherapy targeting solid tumours. This work provides a 
platform for further research into the optimisation of adoptive therapies with CAR-
expressing T cells as a feasible, robust treatment of human cancers. 
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